Prof. P. Rutgeerts

Q: What Schools Are Affiliated With Prof. P. Rutgeerts

Prof. P. Rutgeerts is affiliated with the following schools: KU Leuven

Prof. P. Rutgeerts's AcademicInfluence.com Rankings

Prof. P. Rutgeerts

Philosophy

#2461

World Rank

#4201

Historical Rank

Logic

#597

World Rank

#1069

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Why Is Prof. P. Rutgeerts Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Prof. P. Rutgeerts's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Infliximab for induction and maintenance therapy for ulcerative colitis. (2005) (2903)
A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease (1997) (2858)
Infliximab, azathioprine, or combination therapy for Crohn's disease. (2010) (2727)
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease (2008) (2621)
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci (2010) (2516)
Infliximab for the treatment of fistulas in patients with Crohn's disease. (1999) (2254)
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. (2007) (2091)
Infliximab maintenance therapy for fistulizing Crohn's disease. (2004) (2059)
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. (2003) (1998)
Vedolizumab as induction and maintenance therapy for ulcerative colitis. (2013) (1847)
Vedolizumab as induction and maintenance therapy for Crohn's disease. (2013) (1815)
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. (2006) (1610)
Predictability of the postoperative course of Crohn's disease. (1990) (1576)
A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. (1997) (1359)
Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47 (2011) (1315)
A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis (2013) (1183)
Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. (2004) (1175)
A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. (2007) (1076)
Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. (1999) (1065)
Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. (2016) (1026)
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. (2004) (969)
Ustekinumab induction and maintenance therapy in refractory Crohn's disease. (2012) (945)
Measurement of gastric emptying rate of solids by means of a carbon-labeled octanoic acid breath test. (1993) (905)
Natalizumab induction and maintenance therapy for Crohn's disease. (2005) (887)
Laboratory markers in IBD: useful, magic, or unnecessary toys? (2006) (878)
Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. (2005) (860)
Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives (2011) (857)
Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. (1998) (842)
Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. (2011) (803)
Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. (2014) (780)
Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. (2014) (744)
Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. (2015) (727)
Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. (1995) (725)
Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum (1991) (723)
A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. (2008) (721)
Natural history of recurrent Crohn's disease at the ileocolonic anastomosis after curative surgery. (1984) (711)
Natalizumab for active Crohn's disease. (2003) (691)
Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. (2010) (651)
A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. (2002) (651)
Mucosal healing predicts long‐term outcome of maintenance therapy with infliximab in Crohn's disease (2009) (645)
Deficient host-bacteria interactions in inflammatory bowel disease? The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn’s disease and ulcerative colitis (2004) (638)
Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. (2014) (621)
Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility (2008) (607)
Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. (2007) (602)
The safety of vedolizumab for ulcerative colitis and Crohn's disease (2016) (600)
Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease (2007) (592)
Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility (2019) (589)
Novel Crohn Disease Locus Identified by Genome-Wide Association Maps to a Gene Desert on 5p13.1 and Modulates Expression of PTGER4 (2007) (589)
Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. (2014) (573)
A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. (2005) (564)
A comparison of budesonide with prednisolone for active Crohn's disease. (1994) (557)
Long-term outcome of treatment with infliximab in 614 patients with Crohn’s disease: results from a single-centre cohort (2008) (522)
Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. (2012) (503)
Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. (2008) (500)
Common variants in the NLRP3 region contribute to Crohn's disease susceptibility (2009) (498)
Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. (2009) (495)
Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease (2000) (477)
C-Reactive Protein as a Marker for Inflammatory Bowel Disease (2004) (463)
Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. (2004) (444)
Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. (1999) (444)
Infliximab in the Treatment of Severe, Steroid-Refractory Ulcerative Colitis: A Pilot Study (2001) (432)
Optimizing anti-TNF treatment in inflammatory bowel disease. (2004) (432)
Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. (2003) (426)
Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease (2000) (424)
Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial. (2005) (406)
Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial (2013) (404)
Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. (2001) (401)
Magnetic Resonance Imaging of the Effects of Infliximab on Perianal Fistulizing Crohn's Disease (2003) (393)
Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial (2014) (391)
Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease (2002) (383)
Biological therapies for inflammatory bowel diseases. (2009) (358)
Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial (2014) (345)
Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient (2013) (335)
Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease (2001) (333)
Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis (2009) (330)
Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. (2003) (324)
Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? (2007) (316)
The value of serologic markers in indeterminate colitis: a prospective follow-up study. (2003) (313)
Familial aggregation in Crohn's disease: increased age-adjusted risk and concordance in clinical characteristics. (1996) (308)
Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis. (2006) (295)
Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis. (2014) (294)
Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. (2008) (292)
Toll‐like receptor‐1, ‐2, and ‐6 polymorphisms influence disease extension in inflammatory bowel diseases (2006) (286)
Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. (2006) (273)
Treatment of bleeding gastrointestinal vascular malformations with oestrogen-progesterone (1990) (273)
Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC Randomized Controlled Trials. (2008) (271)
Clustering of increased small intestinal permeability in families with Crohn's disease. (1997) (270)
Budesonide in collagenous colitis: a double-blind placebo-controlled trial with histologic follow-up. (2002) (254)
Oral budesonide for prevention of postsurgical recurrence in Crohn's disease. The IOIBD Budesonide Study Group. (1999) (249)
Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease. (1997) (248)
Review article: infliximab therapy for inflammatory bowel disease – seven years on (2006) (243)
Prognostic Value of Serologic and Histologic Markers on Clinical Relapse in Ulcerative Colitis Patients With Mucosal Healing (2012) (239)
Corticosteroids but not infliximab increase short‐term postoperative infectious complications in patients with ulcerative colitis (2009) (238)
Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept (2005) (237)
The impact of major depressive disorder on the short‐ and long‐term outcome of Crohn's disease treatment with infliximab (2005) (236)
Long-term Outcome of Treatment with Intravenous Cyclosporin in Patients With Severe Ulcerative Colitis (2004) (234)
Histamine Receptor H1-Mediated Sensitization of TRPV1 Mediates Visceral Hypersensitivity and Symptoms in Patients With Irritable Bowel Syndrome. (2016) (233)
Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease (2001) (232)
Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study (2007) (232)
Patchy cecal inflammation associated with distal ulcerative colitis: a prospective endoscopic study. (1997) (230)
Is Ileoscopy With Biopsy Worthwhile in Patients Presenting With Symptoms of Inflammatory Bowel Disease? (1998) (229)
Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease (2004) (228)
American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. (2007) (226)
Adalimumab induces deep remission in patients with Crohn's disease. (2014) (221)
A positive response to infliximab in Crohn disease: Association with a higher systemic inflammation before treatment but not with-308 TNF gene polymorphism (2002) (221)
Mixed triglyceride breath test: a noninvasive test of pancreatic lipase activity in the duodenum. (1989) (221)
The risk of post‐operative complications associated with infliximab therapy for Crohn's disease: a controlled cohort study (2004) (220)
Endoscopic and histologic healing of Crohn's (ileo-) colitis with azathioprine. (1999) (219)
Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease (2002) (219)
Long-term outcome after infliximab for refractory ulcerative colitis. (2008) (212)
NOD2/CARD15 does not influence response to infliximab in Crohn's disease. (2002) (212)
Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection. (2016) (212)
The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease (2014) (212)
Infliximab induces potent anti‐inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn’s disease (2001) (209)
Efficacy and safety of hydrostatic balloon dilatation of ileocolonic Crohn's strictures: a prospective longterm analysis. (1995) (208)
A Pooled Analysis of Infections, Malignancy, and Mortality in Infliximab- and Immunomodulator-Treated Adult Patients With Inflammatory Bowel Disease (2012) (208)
Long‐term Infliximab Maintenance Therapy for Ulcerative Colitis: The ACT‐1 and ‐2 Extension Studies (2012) (207)
Mucosal Gene Expression of Antimicrobial Peptides in Inflammatory Bowel Disease Before and After First Infliximab Treatment (2009) (207)
Influence of dietary protein supplements on the formation of bacterial metabolites in the colon. (1997) (207)
Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study. (1996) (204)
Treatment of Crohn's disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon γ (2002) (201)
Fontolizumab in moderate to severe Crohn's disease: A phase 2, randomized, double‐blind, placebo‐controlled, multiple‐dose study (2010) (200)
Inflammatory Bowel Disease A Positive Response to Infliximab in Crohn Disease: Association with a Higher Systemic Inflammation Before Treatment But Not With -308 TNF Gene Polymorphism (2002) (199)
Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy (2011) (197)
Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. (2000) (195)
Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease (2005) (194)
Predictors of early response to infliximab in patients with ulcerative colitis (2007) (193)
IL-15 Is Highly Expressed in Inflammatory Bowel Disease and Regulates Local T Cell-Dependent Cytokine Production1 (2000) (193)
Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn's disease. (2011) (192)
The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. (2013) (190)
Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. (2000) (189)
Genome-wide association study for ulcerative colitis identifies risk loci at 7q22 and 22q13 (IL17REL) (2010) (186)
An insertion-deletion polymorphism in the interferon regulatory Factor 5 (IRF5) gene confers risk of inflammatory bowel diseases. (2007) (186)
Appendectomy protects against ulcerative colitis. (1994) (185)
Long-term outcome of endoscopic dilatation in patients with Crohn's disease is not affected by disease activity or medical therapy (2009) (184)
Review article: altering the natural history of Crohn's disease – evidence for and against current therapies (2006) (183)
Resequencing of positional candidates identifies low frequency IL23R coding variants protecting against inflammatory bowel disease (2011) (182)
Anti-Saccharomyces Cerevisiae Antibodies (ASCA), Phenotypes of IBD, and Intestinal Permeability: A Study in IBD Families (2001) (181)
Outcome after proctocolectomy with ileal pouch‐anal anastomosis for ulcerative colitis (2008) (180)
Candida albicans Colonization and ASCA in Familial Crohn's Disease (2009) (178)
Donor Species Richness Determines Faecal Microbiota Transplantation Success in Inflammatory Bowel Disease. (2016) (170)
The Effects of Infliximab Therapy on Health-Related Quality of Life in Ulcerative Colitis Patients (2007) (170)
Butyric acid-producing anaerobic bacteria as a novel probiotic treatment approach for inflammatory bowel disease. (2010) (167)
A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon γ antibody, in patients with moderate to severe Crohn’s disease (2005) (164)
Role for Therapeutic Drug Monitoring During Induction Therapy with TNF Antagonists in IBD: Evolution in the Definition and Management of Primary Nonresponse (2015) (163)
Regulatory macrophages induced by infliximab are involved in healing in vivo and in vitro (2012) (163)
Association of organic cation transporter risk haplotype with perianal penetrating Crohn's disease but not with susceptibility to IBD. (2005) (161)
Hyperexpression of CD40 ligand (CD154) in inflammatory bowel disease and its contribution to pathogenic cytokine production. (1999) (157)
Medical Therapy for Crohn's Disease Strictures (2004) (157)
Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease – a SONIC post hoc analysis (2015) (157)
Effects of Lactobacillus casei Shirota, Bifidobacterium breve, and oligofructose-enriched inulin on colonic nitrogen-protein metabolism in healthy humans. (2007) (156)
A panel to predict long-term outcome of infliximab therapy for patients with ulcerative colitis. (2015) (156)
Predictive value of epithelial gene expression profiles for response to infliximab in Crohn's disease‡ (2010) (156)
Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis. (2016) (155)
Genome‐wide association analysis in Primary sclerosing cholangitis and ulcerative colitis identifies risk loci at GPR35 and TCF4 (2013) (153)
Tumour necrosis factor‐α receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab (2004) (153)
Long term results of treatment of vascular malformations of the gastrointestinal tract by neodymium Yag laser photocoagulation. (1985) (152)
Faecal metabolite profiling identifies medium-chain fatty acids as discriminating compounds in IBD (2014) (151)
Controlled trial of YAG laser treatment of upper digestive hemorrhage. (1982) (151)
Genetic risk profiling and prediction of disease course in Crohn's disease patients. (2009) (150)
Association between variants of PRDM1 and NDP52 and Crohn's disease, based on exome sequencing and functional studies. (2013) (149)
Review article: anti‐adhesion therapies for inflammatory bowel disease (2014) (149)
The value of myenteric plexitis to predict early postoperative Crohn's disease recurrence. (2006) (149)
Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC. (2013) (149)
Comparative study of ASCA (Anti-Saccharomyces cerevisiae antibody) assays in inflammatory bowel disease. (2001) (148)
Successful treatment of a squamous papilloma of the hypopharynx‐esophagus by local injections of (S)‐1‐(3‐hydroxy‐2‐phosphonylmethoxypropyl)cytosine (1995) (147)
Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab. (2010) (147)
A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis (2012) (146)
Genetic variation in the autophagy gene ULK1 and risk of Crohn's disease (2011) (146)
Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial (2011) (144)
Overexpression of indoleamine 2,3-dioxygenase in human inflammatory bowel disease. (2004) (144)
Combined carbon-13-glycine/carbon-14-octanoic acid breath test to monitor gastric emptying rates of liquids and solids. (1994) (143)
The role of C-reactive protein as an inflammatory marker in gastrointestinal diseases (2005) (143)
Efficacy and safety of anti‐TNF therapy in elderly patients with inflammatory bowel disease (2015) (142)
Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial. (2011) (141)
Mucosal Gene Expression of Cell Adhesion Molecules, Chemokines, and Chemokine Receptors in Patients With Inflammatory Bowel Disease Before and After Infliximab Treatment (2011) (137)
Genetic Variants of Wnt Transcription Factor TCF-4 (TCF7L2) Putative Promoter Region Are Associated with Small Intestinal Crohn's Disease (2009) (137)
Prevention of Experimental Colitis in SCID Mice Reconstituted with CD45RBhigh CD4+ T Cells by Blocking the CD40-CD154 Interactions1 (2000) (136)
Crohn's disease of the stomach and duodenum: A clinical study with emphasis on the value of endoscopy and endoscopic biopsies. (1980) (134)
Infliximab, Azathioprine, or Infliximab + Azathioprine for Treatment of Moderate to Severe Ulcerative Colitis: The UC Success Trial (2011) (133)
Abatacept for Crohn's disease and ulcerative colitis. (2012) (130)
The efficacy and safety of a third anti‐TNF monoclonal antibody in Crohn’s disease after failure of two other anti‐TNF antibodies (2010) (128)
Confirmation of Multiple Crohn's Disease Susceptibility Loci in a Large Dutch–Belgian Cohort (2009) (128)
Effect of long-term oral glutamine supplements on small intestinal permeability in patients with Crohn's disease. (1999) (127)
Granulomatous gastritis: a morphological and diagnostic approach (1993) (126)
751f One Year Data from the Sonic Study: A Randomized, Double-Blind Trial Comparing Infliximab and Infliximab Plus Azathioprine to Azathioprine in Patients with Crohn's Disease Naive to Immunomodulators and Biologic Therapy (2009) (126)
Increasing incidence of Clostridium difficile-associated diarrhea in inflammatory bowel disease. (2009) (125)
Digestibility of cooked and raw egg protein in humans as assessed by stable isotope techniques. (1998) (124)
Tolerance of arabinoxylan-oligosaccharides and their prebiotic activity in healthy subjects: a randomised, placebo-controlled cross-over study. (2010) (124)
Withdrawal of immunomodulators after co-treatment does not reduce trough level of infliximab in patients with Crohn's disease. (2015) (123)
Early trough levels and antibodies to infliximab predict safety and success of reinitiation of infliximab therapy. (2014) (123)
Correlation Between the Endoscopic and Histologic Score in Assessing the Activity of Ulcerative Colitis (2013) (122)
A randomized trial comparing injection therapy with hemoclip and with injection combined with hemoclip for bleeding ulcers. (2002) (121)
Effect of vedolizumab (anti-α4β7-integrin) therapy on histological healing and mucosal gene expression in patients with UC (2016) (120)
Major histocompatibility class II expression on the small intestinal nervous system in Crohn's disease. (1992) (119)
Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease (2005) (119)
B7 Interactions with CD28 and CTLA-4 Control Tolerance or Induction of Mucosal Inflammation in Chronic Experimental Colitis1 (2001) (119)
Relation between endoscopic ultrasound findings and outcome of patients with tumors of the esophagus or esophagogastric junction. (1997) (118)
Association Between Response to Etrolizumab and Expression of Integrin αE and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis. (2016) (114)
The Multiple Sclerosis Genomic Map: Role of peripheral immune cells and resident microglia in susceptibility (2017) (113)
Current status of genetics research in inflammatory bowel disease (2005) (112)
The value of ileoscopy with biopsy in the diagnosis of intestinal Crohn's disease. (1984) (112)
Efficacy of infliximab in refractory pouchitis and Crohn's disease‐related complications of the pouch: A Belgian case series (2010) (111)
COMPARISON OF ENDOSCOPIC POLIDOCANOL INJECTION AND YAG LASER THERAPY FOR BLEEDING PEPTIC ULCERS (1989) (111)
Mutations in pattern recognition receptor genes modulate seroreactivity to microbial antigens in patients with inflammatory bowel disease (2007) (109)
Diagnostic accuracy of ten second-generation (human) tissue transglutaminase antibody assays in celiac disease. (2004) (109)
Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease. (2018) (109)
Long‐term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy (2018) (108)
Endoscopic balloon dilation of colonic and ileo-colonic Crohn's strictures: long-term results. (1992) (108)
Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease (2008) (107)
Adalimumab for the treatment of fistulas in patients with Crohn’s disease (2009) (106)
Targeting TNF-α for the treatment of inflammatory bowel disease (2014) (105)
Cytochrome P450 3A4 and P‐glycoprotein Activity and Assimilation of Tacrolimus in Transplant Patients with Persistent Diarrhea (2005) (105)
Interferon β-1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study (2003) (104)
Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease (2002) (104)
A20 controls intestinal homeostasis through cell-specific activities (2014) (103)
Reciprocal changes of Foxp3 expression in blood and intestinal mucosa in IBD patients responding to infliximab† (2010) (103)
Self-expandable metallic stents in the palliation of rectosigmoidal carcinoma: a follow-up study. (1998) (102)
Specific members of the predominant gut microbiota predict pouchitis following colectomy and IPAA in UC (2015) (101)
Genetic and Transcriptomic Bases of Intestinal Epithelial Barrier Dysfunction in Inflammatory Bowel Disease (2017) (101)
Future directions in inflammatory bowel disease management. (2014) (101)
Safety and Efficacy of an Oral Inhibitor of the Purinergic Receptor P2X7 in Adult Patients with Moderately to Severely Active Crohn's Disease: A Randomized Placebo-controlled, Double-blind, Phase IIa Study (2015) (100)
Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease (2009) (100)
Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn's disease (2001) (99)
Relation between gastric emptying rate and energy intake in children compared with adults. (1995) (99)
Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn’s disease (2010) (99)
Response and remission are associated with improved quality of life, employment and disability status, hours worked, and productivity of patients with ulcerative colitis (2007) (99)
Post-operative prophylaxis with 6-MP, 5-ASA or placebo in Crohn's disease: A 2 year multicenter trial* (1998) (99)
Treatment of active Crohn's disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): results of a randomized, open‐label, pilot study (2003) (99)
Long-term monitoring of infliximab therapy for perianal fistulizing Crohn's disease by using magnetic resonance imaging. (2011) (98)
Gastric Emptying Rate of Solids in Patients with Nonulcer Dyspepsia (1997) (97)
Impact of lipoteichoic acid modification on the performance of the probiotic Lactobacillus rhamnosus GG in experimental colitis (2010) (97)
Antiadhesion molecule therapy in inflammatory bowel disease. (2002) (96)
Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease (2004) (96)
P087 - SONIC: a randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy (2008) (96)
Baseline microbiota activity and initial bifidobacteria counts influence responses to prebiotic dosing in healthy subjects (2007) (96)
IM-UNITI: 3 Year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease. (2019) (96)
Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies (2016) (95)
Amount and fate of egg protein escaping assimilation in the small intestine of humans. (1999) (95)
The 13C-urea breath test as a predictor of intragastric bacterial load and severity of Helicobacter pylori gastritis. (1998) (94)
Combination Therapy With Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy: A Post Hoc Analysis. (2019) (94)
Chromoendoscopy versus narrow band imaging in UC: a prospective randomised controlled trial (2017) (93)
The Modified Mayo Endoscopic Score (MMES): A New Index for the Assessment of Extension and Severity of Endoscopic Activity in Ulcerative Colitis Patients. (2014) (93)
Epithelioid granulomas, pattern recognition receptors, and phenotypes of Crohn’s disease (2005) (92)
Polymorphisms in innate immunity genes predispose to bacteremia and death in the medical intensive care unit* (2009) (91)
A comparison of laser therapy, plastic stents, and expandable metal stents for palliation of malignant dysphagia in patients without a fistula. (1998) (89)
Effects of infliximab therapy on transmural lesions as assessed by magnetic resonance enteroclysis in patients with ileal Crohn's disease. (2013) (89)
Comparison of Two Adalimumab Treatment Schedule Strategies for Moderate-to-Severe Crohn's Disease: Results From the CHARM Trial (2009) (89)
Proteolytic cleavage and loss of function of biologic agents that neutralize tumor necrosis factor in the mucosa of patients with inflammatory bowel disease. (2015) (88)
Genome wide scan in a Flemish inflammatory bowel disease population: support for the IBD4 locus, population heterogeneity, and epistasis (2004) (87)
Review article: the role of anti‐TNF in the management of ulcerative colitis – past, present and future (2013) (87)
Effect of oligofructose-enriched inulin (OF-IN) on bacterial composition and disease activity of patients with Crohn's disease: results from a double-blinded randomised controlled trial (2011) (86)
Crohn's disease of the esophagus. (1986) (85)
Safety and tolerability of antagonist anti‐human CD40 Mab ch5D12 in patients with moderate to severe Crohn's disease (2005) (85)
Comparative efficacy of coated, oral 5‐aminosalicylic acid (Claversal * ) and sulphasalazine for maintaining remission of ulcerative colitis (1989) (85)
Randomized , Placebo-Controlled Trial of Certolizumab Pegol CDP 870 ) for Treatment of Crohn ’ s Disease (2005) (85)
A randomized placebo-controlled trial of pegylated interferon alpha in active ulcerative colitis (2003) (84)
Starch digestion in normal subjects and patients with pancreatic disease, using a 13CO2 breath test. (1989) (84)
Gene Expression Profiling and Response Signatures Associated With Differential Responses to Infliximab Treatment in Ulcerative Colitis (2011) (84)
The potential for disease modification in Crohn's disease (2010) (83)
Long-Term Effectiveness of Azathioprine in IBD Beyond 4 Years: A European Multicenter Study in 1176 Patients (2006) (83)
In vivo butyrate metabolism and colonic permeability in extensive ulcerative colitis. (1998) (82)
Long-term outcome of patients with Crohn's disease who discontinued infliximab therapy upon clinical remission. (2015) (82)
Impaired butyrate oxidation in ulcerative colitis is due to decreased butyrate uptake and a defect in the oxidation pathway* (2010) (82)
Validation of the lactose-[13C]ureide breath test for determination of orocecal transit time by scintigraphy. (1999) (81)
Morphological identification of alpha‐I‐antitrypsin in the human small intestine (1982) (81)
The Yield of Upper Gastrointestinal Endoscopy in Patients with Suspected Reflux-Related Chronic Ear, Nose, and Throat Symptoms (2004) (81)
A Pilot Study on the Use of the Humanized Anti–Interleukin-2 Receptor Antibody Daclizumab in Active Ulcerative Colitis (2003) (81)
Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases. I. Immunology and therapeutic potential of antiadhesion molecule therapy in inflammatory bowel disease. (2005) (81)
Strategies in the prevention of post-operative recurrence in Crohn's disease. (2003) (79)
Effect of dietary intervention with different pre- and probiotics on intestinal bacterial enzyme activities (2008) (79)
The natural history of esophageal Crohn's disease: three patterns of evolution. (1994) (79)
Review article: non‐malignant haematological complications of anti‐tumour necrosis factor alpha therapy (2012) (78)
Pancreatic Autoantibodies in Inflammatory Bowel Disease (2004) (77)
Pharmacological modulation of gastric emptying rate of solids as measured by the carbon labelled octanoic acid breath test: influence of erythromycin and propantheline. (1994) (77)
Strong Upregulation of AIM2 and IFI16 Inflammasomes in the Mucosa of Patients with Active Inflammatory Bowel Disease (2015) (75)
Environmental Factors in Familial Crohn's Disease in Belgium (2005) (75)
IgG1 heavy chain-coding gene polymorphism (G1m allotypes) and development of antibodies-to-infliximab (2009) (75)
Effect of lactulose and Saccharomyces boulardii administration on the colonic urea‐nitrogen metabolism and the bifidobacteria concentration in healthy human subjects (2006) (75)
Factors associated with short- and long-term outcomes of therapy for Crohn's disease. (2015) (74)
Characteristics of Skin Lesions Associated With AntiTumor Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease (2015) (73)
Metabolism of erythritol in humans: Comparison with glucose and lactitol (1993) (73)
Infliximab induces apoptosis of monocytes and T lymphocytes in a human-mouse chimeric model. (2005) (72)
CXCR1‐binding chemokines in inflammatory bowel diseases: down‐regulated IL‐8/CXCL8 production by leukocytes in Crohn's disease and selective GCP‐2/CXCL6 expression in inflamed intestinal tissue (2004) (72)
Transmission of CARD15 (NOD2) Variants Within Families of Patients with Inflammatory Bowel Disease (2004) (72)
Reliability among central readers in the evaluation of endoscopic findings from patients with Crohn's disease (2015) (72)
Genetic and microbial factors modulating the ubiquitin proteasome system in inflammatory bowel disease (2013) (71)
Recommendations for the treatment of Crohn's disease with tumor necrosis factor antagonists: An expert consensus report (2012) (71)
Cytokine blockade in inflammatory bowel diseases. (2011) (71)
Gastric emptying flow curves separated from carbon-labeled octanoic acid breath test results. (1998) (69)
Metabolic Profiling of the Impact of Oligofructose-Enriched Inulin in Crohn's Disease Patients: A Double-Blinded Randomized Controlled Trial (2013) (69)
Low ileal interleukin 10 concentrations are predictive of endoscopic recurrence in patients with Crohn's disease (2002) (69)
Predictive Model for the Outcome of Infliximab Therapy in Crohn's Disease Based on Apoptotic Pharmacogenetic Index and Clinical Predictors (2007) (69)
A phase II study of laquinimod in Crohn's disease (2014) (68)
Anti-outer membrane of porin C and anti-I2 antibodies in indeterminate colitis (2006) (68)
A randomized, double-blind, placebo-controlled trial of the human anti-TNF-α monoclonal antibody adalimumab for the induction of remission in patients with moderate to severely active Crohn’s disease (2004) (68)
Experimental studies of injection therapy for severe nonvariceal bleeding in dogs. (1989) (68)
Management of Recent Onset Crohn’s Disease: A Controlled, Randomized Trial Comparing Step-up and Top-down Therapy (2005) (67)
Helicobacter pylori infection may undergo spontaneous eradication in children: a 2-year follow-up study. (1998) (67)
Influence of Radiofrequency Energy Delivery at the Gastroesophageal Junction (the Stretta Procedure) on Symptoms, Acid Exposure, and Esophageal Sensitivity to Acid Perfusion in Gastroesophagal Reflux Disease (2007) (67)
Integrated miRNA and mRNA Expression Profiling in Inflamed Colon of Patients with Ulcerative Colitis (2014) (66)
Randomised clinical trial: a placebo‐controlled study of intravenous golimumab induction therapy for ulcerative colitis (2015) (66)
Effects of interleukin 4 on CD25+CD4+ regulatory T cell function. (2005) (66)
Perianal Crohn's disease: classification and clinical evaluation. (2007) (66)
Evaluation of short‐term responsiveness and cutoff values of inflammatory bowel disease questionnaire in Crohn's disease (2006) (66)
Role of interleukin‐12 in the induction of mucosal inflammation and abrogation of regulatory T cell function in chronic experimental colitis (2001) (66)
Onercept for moderate-to-severe Crohn's disease: a randomized, double-blind, placebo-controlled trial. (2006) (64)
Mannan-binding lectin (MBL) gene polymorphisms in ulcerative colitis and Crohn’s disease (2001) (64)
751e Adalimumab Induces and Maintains Mucosal Healing in Patients with Moderate to Severe Ileocolonic Crohn's Disease – First Results of the Extend Trial (2009) (62)
Development of a screening method to determine the pattern of fermentation metabolites in faecal samples using on-line purge-and-trap gas chromatographic-mass spectrometric analysis. (2006) (62)
Sa1922 Pilot Study on the Safety and Efficacy of Faecal Microbiota Transplantation in Refractory Crohn's Disease (2012) (62)
Relationship between the results of pre-treatment urea breath test and efficacy of eradication of Helicobacter pylori infection. (1998) (62)
JC viral loads in patients with Crohn’s disease treated with immunosuppression: can we screen for elevated risk of progressive multifocal leukoencephalopathy? (2008) (61)
Post-Induction Adalimumab Concentration is Associated with Short-Term Mucosal Healing in Patients with Ulcerative Colitis (2017) (61)
13CO2 breath test using naturally 13C-enriched lactose for detection of lactase deficiency in patients with gastrointestinal symptoms. (1988) (61)
Caspase activation and apoptosis induction by adalimumab: Demonstration in vitro and in vivo in a chimeric mouse model (2006) (61)
Anti-TNF agents in Crohn’s disease (2000) (61)
Post Hoc Analysis (2022) (61)
Comparative performances of machine learning methods for classifying Crohn Disease patients using genome-wide genotyping data (2019) (61)
Palliative Nd:YAG laser therapy for cancer of the esophagus and gastroesophageal junction: impact on the quality of remaining life. (1988) (60)
Clinical and genetic factors associated with sacroiliitis in Crohn's disease (2007) (60)
Magnetic resonance enterography is feasible and reliable in multicenter clinical trials in patients with Crohn's disease, and may help select subjects with active inflammation (2016) (60)
Endoscopy in inflammatory bowel diseases (2005) (60)
Bile acid studies in uncomplicated Crohn's disease. (1977) (59)
Classification of inflammatory bowel disease: the old and the new (2012) (58)
Neodymium-YAG laser photocoagulation versus multipolar electrocoagulation for the treatment of severely bleeding ulcers: a randomized comparison. (1987) (58)
Prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis (2014) (57)
Early serial trough and antidrug antibody level measurements predict clinical outcome of infliximab and adalimumab treatment (2011) (57)
Mucosal expression by B7-positive cells of the 60-kilodalton heat-shock protein in inflammatory bowel disease. (1995) (57)
Remission‐inducing effect of anti‐TNF monoclonal antibody in TNBS colitis: Mechanisms beyond neutralization? (2007) (57)
Vedolizumab Induces Long-term Mucosal Healing in Patients With Crohn’s Disease and Ulcerative Colitis (2017) (57)
A pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis. (2003) (56)
Acute infective colitis caused by endemic pathogens in western Europe: endoscopic features. (1982) (56)
Clinical value of the detection of antibodies in the serum for diagnosis and treatment of inflammatory bowel disease. (1998) (56)
Dose-Response Effect of Arabinoxylooligosaccharides on Gastrointestinal Motility and on Colonic Bacterial Metabolism in Healthy Volunteers (2008) (56)
Role of genetics in prediction of disease course and response to therapy. (2010) (56)
Methotrexate in refractory Crohn's disease. (1999) (56)
Involvement of interleukin 18 in Crohn's disease: evidence from in vitro analysis of human gut inflammatory cells and from experimental colitis models (2004) (55)
A mixed-triglyceride breath test for intraluminal fat digestive activity. (1981) (55)
Long-Term Outcome of Patients with Ulcerative Colitis and Primary Non-response to Infliximab. (2016) (55)
Genetic Variation in the Familial Mediterranean Fever Gene (MEFV) and Risk for Crohn's Disease and Ulcerative Colitis (2009) (54)
The ideal management of Crohn's disease: Top down versus step up strategies, a randomized controlled trial (2006) (54)
Increased permeability of macroscopically normal small bowel in Crohn's disease (1994) (54)
Differences in gastric motor activity in renal transplant recipients treated with FK-506 versus cyclosporine. (1999) (54)
Certolizumab pegol, a monthly subcutaneously administered Fc-free anti-TNFα, improves health-related quality of life in patients with moderate to severe Crohn’s disease (2007) (53)
A critical assessment of new therapies in inflammatory bowel disease (2002) (53)
A randomised placebo-controlled multicentre trial of intravenous semapimod HCl for moderate to severe Crohn's disease (2010) (52)
The influence of inulin on the absorption of nitrogen and the production of metabolites of protein fermentation in the colon (2006) (51)
Treatment of severe steroid refractory ulcerative colitis. (2008) (51)
Challenges to the design, execution, and analysis of randomized controlled trials for inflammatory bowel disease. (2012) (50)
Use of anti-tumour necrosis factor agents in inflammatory bowel disease (2001) (50)
Endoscopic laser therapy for palliation of patients with distal colorectal carcinoma: analysis of factors influencing long-term outcome. (2000) (50)
Etanercept in the treatment of active refractory Crohn’s disease: a single-center pilot trial (2001) (50)
A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis. (2003) (50)
Success and failure after repair of rectovaginal fistula in Crohn’s disease: analysis of prognostic factors (2001) (50)
Genetic variants in autophagy-related genes and granuloma formation in a cohort of surgically treated Crohn's disease patients. (2012) (50)
Production of egg proteins, enriched with L-leucine-13C1, for the study of protein assimilation in humans using the breath test technique. (1997) (49)
Extracorporeal Photopheresis (ECP) in Patients with Steroid-dependent Crohn's Disease: An Open-label, Multicenter, Prospective Trial (2013) (49)
The role of vascular endothelial growth factor (VEGF) in inflammatory bowel disease (2006) (49)
The influence of isolated doses of drugs, feeding and colonic bacterial ureolysis on urea breath test results (1995) (49)
A new and effective technique of Yag laser photocoagulation for severe upper gastrointestinal bleeding. (1984) (48)
Antibodies to GP2, the major zymogen granule membrane glycoprotein, in inflammatory bowel diseases (2010) (48)
Mucosal healing and anti TNFs in IBD. (2010) (48)
Oral budesonide for maintenance of remission of Crohn’s disease: a pooled safety analysis (2009) (48)
Association of a Functional Variant in the Wnt Co-Receptor LRP6 with Early Onset Ileal Crohn's Disease (2012) (48)
Serum sickness, encephalitis and other complications of anti-cytokine therapy. (2009) (48)
13C-Octanoic acid breath test for gastric emptying rate of solids. (1998) (48)
Midazolam versus diazepam in lipid emulsion as conscious sedation for colonoscopy with or without reversal of sedation with flumazenil. (1998) (47)
Dysplasia and colorectal cancer in inflammatory bowel disease: a result of inflammation or an intrinsic risk? (2008) (47)
Dysplasia and Cancer in Inflammatory Bowel Disease 10 Years after Diagnosis: Results of a Population-Based European Collaborative Follow-Up Study (2007) (47)
[*C]Octanoic acid breath test to measure gastric emptying rate of solids (1994) (47)
Extracorporeal photopheresis for the treatment of refractory Crohn's disease: Results of an open‐label pilot study (2009) (47)
Etanercept in the treatment of active refractory Crohn's disease: a single-center pilot trial (2001) (46)
Immunohistochemical identification of lysozyme in pseudopyloric gland metaplasia in Crohn's disease. (1983) (46)
Review article: recurrence of Crohn's disease after surgery – the need for treatment of new lesions (2006) (46)
No association between C-reactive protein gene polymorphisms and decrease of C-reactive protein serum concentration after infliximab treatment in Crohn's disease (2006) (46)
Evidence for inflammatory bowel disease of a susceptibility locus on the X chromosome. (2001) (46)
Rifabutin and ethambutol do not help recurrent Crohn's disease in the neoterminal ileum. (1992) (45)
A One-Year Follow-up Study of Endoluminal Gastroplication (Endocinch) in GERD Patients Refractory to Proton Pump Inhibitor Therapy (2005) (45)
The expanding role of biological agents in the treatment of inflammatory bowel disease – focus on selective adhesion molecule inhibition (2003) (45)
Endoscopic injection therapy to prevent rebleeding from peptic ulcers with a protruding vessel: a controlled comparative trial. (1993) (45)
Kinetics of primary bile acids in patients with non‐operated Crohn's disease (1982) (45)
Crohn's disease recurrence can be prevented after ileal resection (2002) (45)
OP11 Individualised infliximab treatment using therapeutic drug monitoring: A prospective controlled Trough level Adapted infliXImab Treatment (TAXIT) trial (2012) (44)
The TNF/ADAM 17 system: implication of an ADAM 17 haplotype in the clinical response to infliximab in Crohn's disease (2006) (44)
Neutrophil Gelatinase B–associated Lipocalin and Matrix Metalloproteinase-9 Complex as a Surrogate Serum Marker of Mucosal Healing in Ulcerative Colitis (2014) (44)
Randomised open controlled trial of colloidal bismuth subcitrate tablets and cimetidine in the treatment of duodenal ulcer. (1980) (43)
Randomised Controlled Trial of Drug Level Versus Clinically Based Dosing of Infliximab Maintenance Therapy in IBD: Final Results of the TAXIT Study (2013) (43)
The relationship between in fl iximab concentrations , antibodies to in fl iximab and disease activity in Crohn ’ s disease (2014) (43)
Relation between gastric emptying rate and rate of intraluminal lipolysis. (1996) (43)
Unique Gene Expression and MR T2 Relaxometry Patterns Define Chronic Murine Dextran Sodium Sulphate Colitis as a Model for Connective Tissue Changes in Human Crohn’s Disease (2013) (43)
Decreased mucosal sulfide detoxification is related to an impaired butyrate oxidation in ulcerative colitis (2012) (43)
Treatment of perianal fistulizing Crohn's disease (2004) (43)
Systematic versus Endoscopy-driven Treatment with Azathioprine to Prevent Postoperative Ileal Crohn's Disease Recurrence. (2014) (43)
Infliximab Restores the Dysfunctional Matrix Remodeling Protein and Growth Factor Gene Expression in Patients with Inflammatory Bowel Disease (2014) (42)
Change in Erythrocyte Mean Corpuscular Volume During Combination Therapy with Azathioprine and Infliximab Is Associated with Mucosal Healing: A Post hoc Analysis from SONIC (2015) (42)
Outcome of surgery for rectovaginal fistula due to Crohn's disease (2009) (42)
Anti-alpha-enolase antibodies in patients with inflammatory Bowel disease. (2008) (42)
Tuberculosis infection following anti-TNF therapy in inflammatory bowel disease, despite negative screening. (2014) (42)
566 Infliximab Concentration and Clinical Outcome in Patients With Ulcerative Colitis (2012) (42)
Activity related increase of exhaled nitric oxide in Crohn's disease and ulcerative colitis: a manifestation of systemic involvement? (1998) (42)
565 Novel Infliximab (IFX) and Antibody-to-Infliximab (ATI) Assays are Predictive of Disease Activity in Patients With Crohn's Disease (CD) (2012) (42)
1159 Results on the Optimisation Phase of the Prospective Controlled Trough Level Adapted Infliximab Treatment (TAXIT) Trial (2012) (42)
Inhibition of glycolipid biosynthesis by N-(5-adamantane-1-yl-methoxy-pentyl)-deoxynojirimycin protects against the inflammatory response in hapten-induced colitis. (2004) (42)
Long-term functional outcome after ileal pouch anal anastomosis in 191 patients with ulcerative colitis. (2014) (41)
High-throughput method for comparative analysis of denaturing gradient gel electrophoresis profiles from human fecal samples reveals significant increases in two bifidobacterial species after inulin-type prebiotic intake. (2011) (41)
Genes Associated with Intestinal Permeability in Ulcerative Colitis: Changes in Expression Following Infliximab Therapy (2012) (41)
Short- and long-term efficacy of cyclosporin administration in patients with acute severe ulcerative colitis. Belgian IBD Group. (1997) (41)
Cystic fibrosis transmembrane conductance regulator gene polymorphisms in patients with primary sclerosing cholangitis. (2009) (41)
Phase I, double‐blind, randomized, placebo‐controlled, dose‐escalation study of NI‐0401 (a fully human anti‐CD3 monoclonal antibody) in patients with moderate to severe active Crohn's disease† (2010) (41)
Test conditions greatly influence permeation of water soluble molecules through the intestinal mucosa: need for standardisation. (1994) (41)
Effects of Ustekinumab on Histologic Disease Activity in Patients with Crohn's Disease. (2019) (41)
Gene Expression Signature for Prediction of Golimumab Response in a Phase 2a Open-Label Trial of Patients With Ulcerative Colitis. (2018) (41)
Influence of Long-Term Administration of Lactulose and Saccharomyces Boulardii on the Colonic Generation of Phenolic Compounds in Healthy Human Subjects (2006) (41)
CDP870, a humanized anti-TNF antibody fragment, induces clinical response with remission in patients with active Crohn's disease (CD) (2003) (41)
Lymphocytes and Langerhans cells in the human oesophageal epithelium (2004) (40)
Inulin is an ideal substrate for a hydrogen breath test to measure the orocaecal transit time (2003) (40)
Transcriptomic analysis of intestinal fibrosis‐associated gene expression in response to medical therapy in Crohn's disease (2008) (39)
Familial aggregation and antimicrobial response dose‐dependently affect the risk for Crohn's disease (2010) (39)
Endoscopic therapy of strictures in Crohn's disease. (2007) (39)
Whipple's disease: a histological, immunocytochemical and electronmicroscopic study of the immune response in the small intestinal mucosa (1992) (39)
Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease. (2002) (38)
Predicting the response to infliximab from trough serum levels (2009) (38)
943b Induction Therapy for Ulcerative Colitis: Results of GEMINI I, a Randomized, Placebo-Controlled, Double-Blind, Multicenter Phase 3 Trial (2012) (38)
Estrogen-progesterone treatment of Osler-Weber-Rendu disease. (1988) (38)
Recent advances: personalised use of current Crohn's disease therapeutic options (2013) (38)
Histologic Appearances of Endoscopic Gastric Mucosal Biopsies 10–20 Years After Partial Gastrectomy (1980) (38)
Interassay and interobserver variability in the detection of anti-neutrophil cytoplasmic antibodies in patients with ulcerative colitis. (2004) (37)
The IL-10R1 S138G loss-of-function allele and ulcerative colitis (2009) (37)
Development of pouchitis following ileal pouch-anal anastomosis (IPAA) for ulcerative colitis: A role for serological markers and microbial pattern recognition receptor genes. (2008) (37)
Pouchitis, Similar to Active Ulcerative Colitis, Is Associated with Impaired Butyrate Oxidation by Intestinal Mucosa (2009) (37)
Medical treatment of inflammatory bowel diseases. (1987) (37)
Anxiety is associated with impaired tolerance of colonoscopy preparation in inflammatory bowel disease and controls. (2013) (37)
Validation of 16S rDNA sequencing in microdissected bowel biopsies from Crohn's disease patients to assess bacterial flora diversity (2006) (37)
Safety and efficacy of Neodymium-Yag laser photocoagulation: an experimental study in dogs. (1981) (37)
Hyperresponsiveness of the Mucosal Barrier in Crohn's Disease Is Not Tumor Necrosis Factor‐Dependent (2005) (37)
Responsiveness of Endoscopic Indices of Disease Activity for Crohn’s Disease (2017) (37)
No Change in Determining Crohn's Disease Recurrence or Need for Endoscopic or Surgical Intervention With Modification of the Rutgeerts' Scoring System. (2019) (37)
Management of acute severe ulcerative colitis (2010) (36)
Analysis of the CC chemokine receptor 5 (CCR5) delta-32 polymorphism in inflammatory bowel disease (2001) (36)
13C-egg white breath test: a non-invasive test of pancreatic trypsin activity in the small intestine (2000) (36)
Serum Neutrophil Gelatinase B-associated Lipocalin and Matrix Metalloproteinase-9 Complex as a Surrogate Marker for Mucosal Healing in Patients with Crohn's Disease. (2015) (36)
Bile acid studies in patients with Crohn's colitis. (1979) (36)
A randomized controlled trial evaluating the ideal medical management for Crohn's disease (CD): Top-down versus step-up strategies (2005) (35)
Molecular Reclassification of Crohn's Disease by Cluster Analysis of Genetic Variants (2010) (34)
Maintenance infliximab (Remicade) is safe, effective and steroid-sparing in Crohn's disease: Preliminary results from the accent i trial (2001) (34)
The long-term morbidity and mortality rate in a cohort of patients with liver cirrhosis and oesophageal varices. (1995) (34)
Tolerability of Shortened Infliximab Infusion Times in Patients With Inflammatory Bowel Diseases: A Single-Center Cohort Study (2011) (34)
DLG5 R30Q is not associated with IBD in Hungarian IBD patients but predicts clinical response to steroids in Crohn's disease. (2006) (34)
Influence of octreotide on the gastric emptying of solids and liquids in normal healthy subjects (1995) (34)
Pharmacogenetics in inflammatory bowel disease. (2006) (34)
A comparative study of colloidal bismuth subcitrate and cimetidine on the healing and recurrence of duodenal ulcer. (1982) (34)
Kinetics of butyrate metabolism in the normal colon and in ulcerative colitis: the effects of substrate concentration and carnitine on the β‐oxidation pathway (2011) (34)
Agreement Between Rectosigmoidoscopy and Colonoscopy Analyses of Disease Activity and Healing in Patients With Ulcerative Colitis. (2016) (34)
Maintenance of Efficacy and Continuing Safety of Golimumab for Active Ulcerative Colitis: PURSUIT-SC Maintenance Study Extension Through 1 Year (2016) (34)
Long‐term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitis (2018) (34)
Adalimumab Rapidly Induces Clinical Remission and Response in Patients with Moderate to Severe Crohnʼs Disease Who Had Secondary Failure to Infliximab Therapy: Results of the GAIN Study (2006) (33)
The future of inflammatory bowel disease management: combining progress in trial design with advances in targeted therapy. (2012) (33)
A rule for determining risk of colorectal cancer in patients with inflammatory bowel disease. (2015) (33)
Identification of a novel autoantigen in inflammatory bowel disease by protein microarray (2011) (33)
405 High Infliximab Trough Levels are Associated With Mucosal Healing in Crohn's Disease (2010) (33)
Mucosal Healing and Long‐term Outcomes of Patients With Inflammatory Bowel Diseases Receiving Clinic‐Based vs Trough Concentration‐Based Dosing of Infliximab (2017) (33)
Crohn's Disease and Month of Birth (2005) (33)
Medical management of postoperative recurrence in Crohn's disease. (2004) (32)
Significant Differences Between Crohn’s Disease and Ulcerative Colitis Regarding the Impact of Body Mass Index and Initial Disease Activity on Responsiveness to Azathioprine: Results from a European Multicenter Study in 1,176 Patients (2010) (32)
LONG-TERM OUTCOME OF TREATMENT WITH INFLIXIMAB IN 440 CROHN'S DISEASE PATIENTS: RESULTS FROM A SINGLE CENTER COHORT (2007) (32)
Randomised non‐inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild‐to‐moderate ulcerative colitis (2017) (32)
Characterisation of Mucosal Healing with Adalimumab Treatment in Patients with Moderately to Severely Active Crohn’s Disease: Results from the EXTEND Trial (2016) (32)
A placebo controlled trial of metronidazole for recurrence prevention of Crohn's disease after resection of the terminal ileum (1992) (32)
Gene and Mirna Regulatory Networks During Different Stages of Crohn's Disease. (2019) (31)
13CO2 breath test to measure the hydrolysis of various starch formulations in healthy subjects. (1990) (31)
Influence of nutritional substrates on the formation of volatiles by the fecal flora. (1991) (31)
Effects of anti‐tumour necrosis factor, interleukin‐10 and antibiotic therapy in the indometacin‐induced bowel inflammation rat model (2001) (31)
Proctitis and rectal stenosis induced by nonsteroidal antiinflammatory suppositories. (1993) (30)
Restorative proctocolectomy in elective and emergency cases of ulcerative colitis (1994) (30)
Protein-losing enteropathy in Crohn's disease. (2005) (30)
Genetic Evidence Supporting the Association of Protease and Protease Inhibitor Genes with Inflammatory Bowel Disease: A Systematic Review (2011) (30)
Effects of haptoglobin polymorphisms and deficiency on susceptibility to inflammatory bowel disease and on severity of murine colitis (2011) (29)
Validation of lactose[15N,15N]ureide as a tool to study colonic nitrogen metabolism. (2005) (29)
Gastric emptying flow curves separated from carbon-labeled octanoic acid breath test results. (1998) (29)
Ileal dysfunction and bacterial overgrowth in patients with Crohn's disease. (1981) (29)
Interleukin-1 receptor antagonist VNTR-polymorphism in inflammatory bowel disease (2002) (29)
Sa1198 Agreement Among Experts in the Endoscopic Evaluation of Postoperative Recurrence in Crohn's Disease Using the Rutgeerts Score (2014) (29)
Lack of efficacy of ridogrel, a thromboxane synthase inhibitor, in a placebo‐controlled, double‐blind, multi‐centre clinical trial in active Crohn’s disease (2001) (29)
Contribution of genetic and environmental factors in the pathogenesis of Crohn's disease in a large family with multiple cases (2007) (29)
Conventional treatment of Crohn's disease: objectives and outcomes. (2001) (29)
Efficacy and safety of hydrostatic balloon dilation of ileocolonic Crohn's strictures. A prospective long-term analysis. (1994) (28)
Adalimumab Induces and Maintains Clinical Response and Remission in Patients With Active Crohn’s Disease: Results of the CHARM Trial (2006) (28)
Understanding inflammatory bowel disease--the clinician's perspective. (2001) (28)
In vivo Influence of Nicotine on Human Basal and NSAID-induced Gut Barrier Function (2003) (28)
Review article: treatment of perianal fistulizing Crohn's disease. (2004) (28)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase2b Study of Ustekinumab, a Human Monoclonal Antibody to IL-12/23p40, in Patients With Moderately to Severely Active Crohn's Disease: Results Through Week 22 From the Certifi Trial (2011) (28)
943d A Phase 2/3 Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Subcutaneous Golimumab Induction Therapy in Patients with Moderately to Severely Active Ulcerative Colitis: PURSUIT SC (2012) (28)
Submucosal tumors of the colon: Experience with twenty-five cases (1978) (28)
Detection of Antisynthetic Mannoside Antibodies (AΣMA) Reveals Heterogeneity in the ASCA Response of Crohn's Disease Patients and Contributes to Differential Diagnosis, Stratification, and Prediction (2008) (27)
Involvement of the upper digestive tract by systemic neurofibromatosis. (1981) (27)
Medical treatment of inflammatory bowel diseases (2005) (27)
Infliximab administered with shortened infusion times in a specialized IBD infusion unit: a prospective cohort study. (2010) (27)
Involvement of 4‐1BB (CD137)−4‐1BBligand interaction in the modulation of CD4+ T cell‐mediated inflammatory colitis (2006) (27)
Eldelumab [anti-interferon-&ggr;-inducible protein-10 antibody] Induction Therapy for Active Crohn’s Disease: a Randomised, Double-blind, Placebo-controlled Phase IIa Study (2017) (27)
Lymphotoxin alpha gene in Crohn's disease patients: absence of implication in the response to infliximab in a large cohort study (2006) (27)
Push enteroscopy. Technique, depth, and yield of insertion. (1996) (27)
494 Efficacy and Safety of Certolizumab Pegol in Patients with Active Crohn's Disease Who Previously Lost Response or Were Intolerant to Infliximab: Open-Label Induction Preliminary Results of the Welcome Study (2008) (27)
Validation of a new test meal for a protein digestion breath test in humans. (2004) (26)
Effects of acarbose on starch hydrolysis (1992) (26)
EPILEPSY Felbamate: a new antiepileptic drug (1993) (26)
Whipple's disease: endoscopic aspects before and after therapy. (1990) (26)
Diagnostic approach to IBD. (2000) (26)
Impact of the synbiotic combination of Lactobacillus casei shirota and oligofructose-enriched inulin on the fecal volatile metabolite profile in healthy subjects. (2011) (26)
The cellular composition of granulomas in mesenteric lymph nodes from patients with Crohn's disease (2004) (26)
Superior Endoscopic and Deep Remission Outcomes in Adults with Moderate to Severe Crohn's Disease Managed with Treat to Target Approach Versus Clinical Symptoms: Data from Calm (2017) (25)
Performance of Crohn's disease Clinical Trial Endpoints based upon Different Cutoffs for Patient Reported Outcomes or Endoscopic Activity: Analysis of EXTEND Data. (2018) (25)
Symptomatic gastrointestinal metastases from malignant melanoma. A clinical study. (1988) (25)
Safety issues with biological therapies for inflammatory bowel disease (2006) (25)
Systematic ileocolonoscopy and bowel biopsy study in spondylarthropathy. (1987) (25)
An historical overview of the treatment of Crohn's disease: why do we need biological therapies? (2004) (25)
Adalimumab in Crohn’s disease (2007) (25)
New Drug Therapies on the Horizon for IBD (2012) (25)
Current Status of Endoscopic Hemostasis for Severely Bleeding Ulcers (1988) (25)
Mannan binding lectin (MBL) gene polymorphisms are not associated with anti-Saccharomyces cerevisiae (ASCA) in patients with Crohn’s disease (2006) (25)
Long-term Safety of Vedolizumab for the Treatment of Ulcerative Colitis or Crohn's Disease (2013) (25)
Whipple's disease: the value of upper gastrointestinal endoscopy for the diagnosis and follow-up. (1992) (25)
Measurement of hepatic and intestinal CYP3A4 and PGP activity by combined po + iv [14C]erythromycin breath and urine test. (2003) (24)
Safety, tolerance and efficacy of multiple doses of subcutaneous interleukin-10 in mild to moderate active Crohn's disease (STAMM-CD) (1998) (24)
Intravenous iron therapy restores functional iron deficiency induced by infliximab. (2007) (24)
Duration of response following cessation of infliximab therapy for active or fistulizing Crohn's disease (1999) (24)
Amount and fate of egg protein escaping assimilation in the small intestine of humans. (1999) (24)
NOD2/CARD15 mutations in Croatian patients with Crohn's disease: prevalence and genotype–phenotype relationship (2006) (24)
Antibody responses in Crohn's disease. (2004) (24)
A phase III, double-blind, placebo-controlled study of the efficacy, safety, and tolerability of antegren (Natalizumab) in maintaining clinical response and remission in Crohn’s disease (ENACT-2) (2004) (24)
Tissue damage produced by hemostatic injections (1986) (23)
Medical Therapy of Inflammatory Bowel Disease (1998) (23)
EFFECTS OF LACTOBACILLUS CASEI SHIROTA , BIFIDOBACTERIUM BREVE , AND OLIGOFRUCTOSE-ENRICHED INULIN ON THE COLONIC NITROGEN-PROTEIN METABOLISM IN HEALTHY HUMANS Pre-and probiotics on colonic metabolism 5 (2006) (23)
T1239 Adalimumab Treatment Results in Deep Remission for Patients With Moderate to Severe Ileocolonic Crohn's Disease: Results From EXTEND (2010) (23)
In vivo evaluation of a colonic delivery system using isotope techniques (2005) (23)
Efficacy and Safety of Adalimumab by Disease Duration: Analysis of Pooled Data From Crohn’s Disease Studies (2019) (23)
Seroreactivity against glycolytic enzymes in inflammatory bowel disease (2011) (23)
901 Effect of the H1-Receptor Antagonist Ebastin on Visceral Perception and Clinical Symptoms in IBS (2013) (23)
Restoration of Foxp3+ Regulatory T-cell Subsets and Foxp3− Type 1 Regulatory-like T Cells in Inflammatory Bowel Diseases During Anti-tumor Necrosis Factor Therapy (2015) (23)
Agreement of site and central readings of ileocolonoscopic scores in Crohn's disease: comparison using data from the EXTEND trial. (2016) (22)
Gastric emptying and Helicobacter pylori infection in duodenal ulcer disease. (1996) (22)
Anti–Tumor Necrosis Factor Therapy Restores Peripheral Blood B-cell Subsets and CD40 Expression in Inflammatory Bowel Diseases (2015) (22)
What is the role of endoscopy in the postoperative management of Crohn's disease? (2008) (22)
Intersphincteric proctectomy with end-colostomy for anorectal Crohn's disease results in early and severe proximal colonic recurrence. (2013) (22)
Maintenance of Remission over 1 Year in Patients with Active Crohnʼs Disease Treated with Adalimumab: Results of a Blinded, Placebo-Controlled Study (2005) (22)
Short-term Effect of Infliximab Is Reflected in the Clot Lysis Profile of Patients with Inflammatory Bowel Disease: A Prospective Study (2015) (22)
Effects of T cell‐induced colonic inflammation on epithelial barrier function† (2010) (22)
Familial Crohn's Disease in Belgium: Pedigrees, Temporal Relationships Among Cases, and Family Histories (2007) (22)
Decreased lamina propria effector cell responsiveness to interleukin-10 in ileal Crohn's disease. (2002) (22)
Infliximab therapy for patients with inflammatory bowel disease: 10 years on. (2009) (21)
(Auto)antibodies in inflammatory bowel diseases. (2008) (21)
A microscopic and ultrastructural study hemostasis after laser photocoagulation. (1980) (20)
Vedolizumab Maintenance Therapy for Ulcerative Colitis: Results of GEMINI I, a Randomized, Placebo-Controlled, Double-Blind, Multicenter Phase 3 Trial: 1522 (2012) (20)
Etanercept (TNF receptor fusion protein, enbrel®) is effective and well tolerated in active refractory Crohn's disease: Results of a single center pilot trial (2000) (20)
Intentional treatment with infliximab during pregnancy in women with inflammatory bowel disease (2007) (20)
Correlation of Stool Frequency and Abdominal Pain Measures With Simple Endoscopic Score for Crohn's Disease. (2019) (20)
Long-Term Benefit of Golimumab for Patients with Moderately to Severely Active Ulcerative Colitis: Results from the PURSUIT-Maintenance Extension (2018) (20)
Successful treatment of human papillomavirus (HPV) associated giant squamous papilloma of the hypopharynx and esophagus by local injections of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) (1994) (20)
Focus on mechanisms of inflammation in inflammatory bowel disease sites of inhibition: current and future therapies. (2006) (20)
Long‐term effect of hormonal therapy for bleeding gastrointestinal vascular malformations (1993) (20)
The urea breath test: a non-invasive clinical tool for detecting Helicobacter pylori infection. (1995) (19)
Infliximab (Remicade) treatment in Crohn's disease and antinuclear antibody (ANA) formation (2001) (19)
Postoperative recurrence of Crohn's disease: pathophysiology and prevention. (1999) (19)
Porous-layer open-tubular gas chromatography in combination with an ion trap detector to assess volatile metabolites in human breath. (1989) (19)
OP10 Importance of trough levels and antibodies on the long-term efficacy of infliximab therapy in ulcerative colitis (2012) (19)
T lymphocyte subsets in reflux esophagitis and esophageal Crohn's disease (1984) (19)
Positive 14CO2 bile acid breath test in elderly people. (1984) (19)
Radiofrequency delivery at the gastroesophageal junction in GERD improves acid exposure and symptoms and decreases esophageal sensitivity to acid infusion (2003) (19)
Treatment of esophagorespiratory fistulas with a polyurethane-covered self-expanding metallic mesh stent. (1996) (19)
Difference in Pathomechanism Between Crohn's Disease and Ulcerative Colitis Revealed by Colon Transcriptome. (2018) (19)
O08 Concomitant Immunosuppression Does Not Impact on the Outcome Of Maintenance Infliximab Therapy in Crohn's Disease: Final Results of the Imid Trial (2007) (19)
Evaluation of the Given Patency System in the GI Tract: Results of a Multi-Center Study (2004) (18)
Dysplasia in inflammatory bowel diseases: definition and clinical impact. (1999) (18)
Whipple's disease: A histological, immunocytochemical, and electron microscopic study of the small intestinal epithelium (1994) (18)
Ileocolonoscopy and spondarthritis. (1988) (18)
HACA formation after infliximab (Remicade™) treatment in Crohn's disease is clearly associated with infusion reactions (2001) (18)
Effects on bowel motility of misoprostol administered before and after meals (1991) (18)
A novel susceptibility locus for Crohn's disease identified by whole genome association maps to a gene desert on chromosome 5p13.1 and modulates the level of expression of the prostaglandin receptor EP4 (2005) (18)
768 A Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Ustekinumab Maintenance Therapy in Moderate - Severe Crohn's Disease Patients: Results From IM-UNITI (2016) (18)
Rates of Post-operative Recurrence of Crohn's Disease and Effects of Immunosuppressive and Biologic Therapies. (2020) (18)
Measurement of the rate of assimilation of oligo- and polysaccharides by 13CO2 breath tests and isotope ratio mass spectrometry. (1988) (18)
Postoperative recurrence of Crohn's disease: Pathophysiology and prevention (1999) (17)
Drug safety evaluation of certolizumab pegol (2014) (17)
Miliary tuberculosis following infliximab therapy for Crohn disease: A case report and review of the literature. (2006) (17)
MEDICAL THERAPY FOR CROHN'S DISEASE (1998) (17)
Higher Levels of Infliximab may Alleviate the Need of Azathioprine Comedication in the Treatment of Patients with Crohn's Disease: A Sonic Post HOC Analysis (2017) (17)
O09 Severe Postoperative Recurrence of Crohn's Disease (CD) Is Significantly Reduced With Combination Therapy Metronidazole + Azathioprine: A Double-Blind Controlled Randomized Trial (2007) (17)
Functional expression of 4-1BB (CD137) in the inflammatory tissue in Crohn's disease. (2004) (17)
Ornidazol for prophylaxis of postoperative Crohn's disease: final results of a double blind placebo controlled trial (2002) (17)
946 Corticosteroids Pose An Increased Risk for Serious Infection: An Interim Safety Analysis of the ENCORE Registry (2008) (17)
Nitroimidazol antibiotics are efficacious for prophylaxis of postoperative recurrence of Crohn's disease: a placebo controlled trial (1999) (16)
Management of loss of response to anti-TNF drugs: Change the dose or change the drug? (2008) (16)
The effect of dose escalation on trough levels in patients who lost response to infliximab (2010) (16)
Emerging Biological Treatments in Inflammatory Bowel Diseases (2006) (16)
Screening method for the determination of volatiles in biomedical samples by means of an off-line closed-loop trapping system and high-resolution gas chromatography-ion trap detection. (1994) (16)
Biliary lipid composition in patients with nonoperated Crohn's disease (2005) (16)
OC-043 Long term efficacy and safety of ustekinumab for crohn’s disease: results from im-uniti long-term extension through 2 years (2017) (16)
Infectious agents in inflammatory bowel disease. (1992) (15)
Double-blinded, randomized, placebo-controlled trial of the remission inducing and steroid sparing properties of two schedules of ISIS 2302 (ICAM-1 antisense) in active, steroid-dependent crohn's disease (2000) (15)
Early lesions in the neoterminal ileum after Crohn's resection do not originate from identifiable microscopic inflammation (1986) (15)
MANAGEMENT OF ULCERATIVE COLITIS AND CROHN’S DISEASE (2004) (15)
Reliability of Endoscopic Evaluation of Postoperative Recurrent Crohn's Disease. (2020) (15)
Inflammatory bowel disease and colitis: new concepts from the bench and the clinic (2011) (15)
MRI imaging of the effects of infliximab in perianal fistulizing Crohn's disease (2001) (15)
Long-term outcome of treatment with cyclosporine IV for patients with intractable ulcerative colitis (2001) (15)
[Histopathologic diagnosis of the activity of chronic inflammatory bowel disease. Evaluation of the effect of drug treatment. Use of histological scores]. (1999) (15)
From Aphthous Ulcer to Full-Blown Crohn’s Disease (2011) (14)
Colorectal cancer in colonic Crohn's disease--high frequency of DNA-aneuploidy. (2005) (14)
Endoscopic therapy for upper gastrointestinal hemorrhage: a state of the art. (1999) (14)
A randomised placebo controlled trial of pegylated interferon α in active ulcerative colitis (2003) (14)
Analysis for short-chain carboxylic acids in feces by gas chromatography with an ion-trap detector (1991) (14)
W1133 Mucosal Healing Predicts Sustained Clinical Remission in Early Crohn's Disease (2008) (14)
Intestinal expression of SHIP in inflammatory bowel diseases (2011) (14)
Primary gastric actinomycosis: a case report and review of the literature. (1984) (14)
In vitro analysis of interferon gamma (IFN-gamma) and interleukin-12 (IL-12) production and their effects in ileal Crohn's disease. (2002) (14)
Transendoscopic Doppler ultrasound: usefulness for diagnosis and treatment of vascular malformations. (1988) (14)
Optimizing treatment of inflammatory bowel diseases with biologic agents (2008) (13)
Prevalence and significance of perinuclear anti-neutrophil antibodies (pANCA) in Romanian patients with Crohn's disease and ulcerative colitis. (2005) (13)
Stable Isotopes and 13CO2 Breath Tests for Investigating Gastrointestinal Functions (2002) (13)
Immune reactivity to β-tubulin isotype 5 and vesicular integral-membrane protein 36 in patients with autoimmune gastrointestinal disorders (2010) (13)
Recombinant human interferon-beta (IFNβ-1a) induces remission and is well tolerated in moderately active ulcerative colitis (UC) (2001) (13)
Randomized placebo controlled trial of pro- and prebiotics (synbiotics cocktail) for maintenance of infliximab induced remission of luminal Crohn's disease (CD) (2004) (13)
How to Guide Therapeutic Decisions in a Patient-Tailored Approach to Treatment of IBD? (2012) (13)
Serological diagnosis of inflammatory bowel disease. (2000) (13)
Early dose optimization of golimumab in nonresponders to induction treatment for ulcerative colitis is effective and supported by pharmacokinetic data. (2019) (13)
Endoscopic sclerotherapy of esophageal varices. Long-term follow-up, recurrence, and survival. (1988) (13)
Interleukin‐15 receptor α expression in inflammatory bowel disease patients before and after normalization of inflammation with infliximab (2013) (13)
Endoscopy in inflammatory bowel disease. (1989) (13)
A new method for the measurement of bile acid turnover and pool size by a double label, single intubation technique. (1981) (13)
159 Differentiation Between Etrolizumab (Rhumab Beta7) and Placebo in the Eucalyptus Phase II Randomized Double-Blind Placebo-Controlled Induction Study to Evaluate Efficacy and Safety in Patients With Refractory Moderate-to-Severely Active Ulcerative Colitis (2013) (13)
Erratum: Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47 (Nature Genetics (2011) 43 (246-252)) (2011) (13)
INFLAMMATORY BOWEL DISEASE Crohn's disease and pre-aphthoid lesions (1993) (13)
Endoscopic findings in the neoterminal ileum within one year of surgery for Crohn's disease accurately predict further endoscopic and clinical outcome (1987) (13)
Hypertrophic lymphocytic gastritis with a gastric carcinoma. (1998) (13)
Immunogenicity of Golimumab and its Clinical Relevance in Patients With Ulcerative Colitis. (2019) (12)
Non-variceal upper gastrointestinal bleeding. (2001) (12)
Risk factors which determine the long term outcome of Neodymium-YAG laser palliation of colorectal carcinoma (2005) (12)
Response to anti-tnfatreatment is associated with the TNFA-308*1 allele (2000) (12)
NOD 2 / CARD 15 Does Not Influence Response to Infliximab in Crohn ' s Disease * (2009) (12)
Saccharomyces boulardii in Crohn's disease: effect on anti-Saccharomyces cerevisiae antibodies and intestinal permeability. (2005) (12)
11 Vedolizumab induction therapy for patients with Crohn's disease and prior anti-tumour necrosis factor antagonist failure: a randomised, placebo-controlled, double-blind, multicentre trial (2013) (12)
Sustained Clinical Remission in Patients with Moderate to Severe Crohnʼs Disease with Adalimumab, Regardless of Anti-TNF History or Concomitant Immunosuppressant Therapy: 1173 (2006) (12)
The presence and severity of neural inflammation predict severe postoperative recurrence of Crohn's disease (1998) (12)
TNF-alpha antibody therapy causes a fast and dramatic decrease of histologic colonic inflammation in Crohn's disease but not in ulcerative colitis (1996) (12)
Sclerotherapy of oesophageal varices after variceal haemorrhage. (1984) (12)
Crohn's Disease: Infliximab Trough Levels and CRP During Infliximab-Immunomodulator Combination Treatment Are Associated With Clinical Outcome After Immunomodulator Withdrawal (2011) (12)
Anti- and proinflammatory effects of interleukin-10 in mild to moderate Crohn's disease (1999) (12)
Assessment of the Microbiota in Microdissected Tissues of Crohn's Disease Patients (2011) (12)
Prevention of early recurrence of Crohn's disease after ileal resection with ileocolonic anastomosis (1994) (11)
Early Serum Infliximab Trough Level, Clinical Disease Activity and CRP as Markers of Sustained Benefit of Infliximab Treatment in Crohnʼs Disease: A Post-hoc Analysis of the ACCENT1 Trial: 1226 (2011) (11)
Clustering of (auto)immune diseases with early-onset and complicated inflammatory bowel disease (2008) (11)
Rectal non-Hodgkin's lymphoma in an infliximab treated patient with ulcerative colitis and primary sclerosing cholangitis. (2010) (11)
46 A Phase 2a Randomized Placebo-Controlled Double-Blind Multi-Center Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of AG011 in Patients With Moderately Active Ulcerative Colitis (2010) (11)
644 Early Mucosal Healing Status Predicts Long-Term Clinical Benefits for Adalimumab-Treated Patients With Moderate to Severe Crohn's Disease (2010) (11)
563 Antibodies to Infliximab Can Either Be Persistent or Transient: A Retrospective Case-Control Study in IBD Patients Treated With Infliximab Maintenance Therapy (2012) (11)
Letter: dry blood spots for anti‐TNF treatment monitoring in IBD (2013) (11)
Recombinant soluble p55 TNF receptor induces remission, is non-immunogenic and well tolerated in active Crohn's disease: Results of a randomized pilot trial (2001) (11)
Influence of resistant starch alone or combined with wheat bran on gastric emptying and protein digestion in healthy volunteers (2007) (11)
Immunosuppressive activity of a new pteridine derivative (4AZA1378) alleviates severity of TNBS-induced colitis in mice. (2007) (11)
Concordance in Anti-OmpC and Anti-I2 Indicate the Influence of Genetic Predisposition: Results of a European Study of Twins with Crohn's Disease. (2016) (11)
A model for calculating the hospital costs for pediatric endoscopy. (1996) (11)
How to avoid water contamination in the thermodesorption cryofocusing technique. Application to ethane analysis in human breath by means of an ion trap detector (ITD) (1989) (11)
649 A Randomized Placebo-Controlled Trial of Abatacept for Moderately-to-Severely Active Crohn's Disease (CD) (2010) (11)
Endoscopic definitions of esophagogastric junction regional anatomy (2000) (11)
Recurrence of Crohn's disease in the neoterminal ileum after ileal resection: is prevention therapy possible? (1994) (11)
Long-term outcome of endoscopic dilatation in patients with Crohn's disease is not affected by disease activity or medical therapy (vol 59, pg 320, 2010) (2010) (11)
Anti-inflammatory activity of a pteridine derivative (4AZA2096) alleviates TNBS-induced colitis in mice. (2006) (10)
Achievement of Early Deep Remission Predicts Better Long-Term Outcomes for Adalimumab-Treated Patients with Crohnʼs Disease: Data from EXTEND: 1190 (2010) (10)
749 Infliximab for Prevention of Recurrence of Post-Surgical Crohn's Disease Following Ileocolonic Resection: A Randomized, Placebo-Controlled Study (2015) (10)
Vedolizumab Maintenance Therapy for Crohnʼs Disease: Results of GEMINI II, a Randomized, Placebo-Controlled, Double-Blind, Multi-center Phase 3 Trial: 1542 (2012) (10)
The use of humanized, anti interleukin-2 receptor antibodies (Zenapax®, Roche) in refractory ulcerative colitis (2001) (10)
The use of oral topically acting glucocorticosteroids in the treatment of inflammatory bowel disease. (1998) (10)
Infliximab Results in Reduction of Inflammation and Inflammatory Markers in the Mucosa of Ulcerative Colitis Patients: The ACT 1 Trial (2005) (10)
Effects of natalizumab on gut healing in a phase 3 study of active Crohn's disease therapy (ENACT-1) (2004) (10)
Management of perianal Crohn's disease. (2000) (10)
Sustained Therapeutic Benefit of Vedolizumab Throughout 1 Year in Ulcerative Colitis in GEMINI I, a Randomized, Placebo‐Controlled, Double‐Blind, Multicenter Trial: P‐27 (2012) (10)
T1048 No New Safety Signals Identified in Crohn's Disease Patients Treated with Infliximab in An Interim Review of the ENCORE Registry (2008) (10)
The enterohepatic circulation of bile acids during continuous liquid formula perfusion of the duodenum. (1983) (10)
Anti-TNFα monoclonal antibody (cA2) produces endoscopic healing in patients with treatment-resistant, active Crohn's disease (1998) (10)
143 Welcome: A Randomized, Double-Blind, Controlled Trial Comparing Certolizumab Pegol 400 Mg Every 2 Weeks with Every 4 Weeks for Maintenance of Response and Remission in Patients with Moderate to Severe Crohn's Disease with Secondary Failure to Infliximab (2009) (10)
Immunosuppression in inflammatory bowel disease: traditional, biological or both? (2009) (10)
Exclusion of linkage of Crohn's disease to previously reported regions on chromosomes 12, 7, and 3 in the Belgian population indicates genetic heterogeneity. (2000) (10)
Recurrence of Crohn's lesions in the neoterminal ileum after ileal resection and ileocolonic anastomosis. (1990) (10)
13CO2-Breath Tests in Nutritional Diagnosis: Present Applications and Future Possibilities (1986) (10)
Expression of MHC Class II antigens by oesophageal epithelium in herpes simplex oesophagitis (1985) (10)
Inflammation‐Induced Downregulation of Butyrate Uptake and Oxidation Is Not Caused by a Reduced Gene Expression (2015) (10)
M1143 Benefits of Dosage Adjustment with Adalimumab in Crohn's Disease: An Analysis of the CHARM Trial (2008) (10)
Little benefit from mesalazine taken prophylactically after surgery for Crohn's disease (2001) (9)
The use of budesonide in the treatment of active Crohn's disease is good clinical practice. (2001) (9)
Differential p38 Mitogen-Activated Protein Kinase Target Phosphorylation in Responders and Nonresponders to Infliximab (2003) (9)
Octreotide for the treatment of diarrhoea in patients with ileal pouch anal anastomosis: a placebo‐controlled crossover study (2012) (9)
A Phase I Study of rHuMab Beta7 in Moderate to Severe Ulcerative Colitis (UC) (2011) (9)
Role of biomarkers in the diagnosis of inflammatory bowel disease. (2007) (9)
Replication of linkage on 14Q11-12 in inflammatory bowel disease (IBD) (2000) (9)
Infliximab reduces colectomy in patients with moderate-to-severe ulcerative colitis: colectomy analysis from ACT 1 and ACT 2: O-006. (2008) (9)
Serological markers in inflammatory bowel disease (2008) (9)
Lymphocytic population of the normal esophageal epithelium (1983) (9)
41a Prediction of Long-Term Clinical Remission for Adalimumab-Treated Patients With Crohn's Disease by Identification of Appropriate Dichotomizing Points for SES-CD (2010) (9)
Mucosal Healing in Patients with Ulcerative Colitis Associates with a Reduced Colectomy Risk, High Incidence of Symptomatic Remission, and Corticosteroid-Free State: 1200 (2010) (9)
Variceal band ligation in the management of bleeding oesophageal varices: an overview. (2001) (9)
Infliximab for ulcerative colitis: the need for adequately powered placebo-controlled trials (2002) (9)
Magnesium chloride slows gastric emptying, but does not affect digestive functions (2002) (9)
Modern Therapy for Inflammatory Bowel Disease (2003) (9)
The benefits of endoscopy in upper gastrointestinal bleeding. (1986) (9)
Changes in small intestinal epithelial expression of MHC Class II antigen after terminal ileal resection for Crohn's disease (1988) (8)
Mo1665 Prognostic Value of Serologic and Histologic Markers on Long-Term Outcomes in Ulcerative Colitis Patients With Mucosal Healing (2012) (8)
What is the role of endoscopy in predicting Crohn's disease relapse or course? (2008) (8)
The yag laser microulcer a reproducible and safe model for the study of cytoprotection in man (1986) (8)
M1222 Evolution of Endoscopic Activity Scores Under Placebo Therapy in Crohn's Disease (2010) (8)
407 Anti-TNFα Induced Severe Arthralgia as a Manifestation of Autoimmunity? (2010) (8)
Immunosuppression-associated lymphoma in IBD (2009) (8)
Optimizing biologic therapies for inflammatory bowel disease (ulcerative colitis and crohn’s disease) (2009) (8)
P285 Agreement among experts in the endoscopic evaluation of postoperative recurrence in Crohn's disease using the Rutgeerts score (2014) (8)
Significance of anti-sacharomices cerevisiae antibodies (ASCA) in patients with inflammatory bowel diseases in Romania. (2005) (8)
Are anti-saccharomyces cerevisiae antibodies (ASCA) and perinuclear antineutrophil cytoplasmic antibodies (PANCA) useful in indeterminate colitis? A prospective follow-up study (2000) (8)
OP024 Agreement among central readers in the evaluation of endoscopic disease activity in Crohn's disease (2014) (8)
The influence of 15(R)-15 methyl PGE2, methyl ester, on Nd:YAG laser-induced gastric ulcers. (1984) (8)
Clinical and genetic factors associated with sacroi liitis in Crohn's disease (2008) (8)
Demonstration of nitric oxide positive neurons in Crohn's disease (1993) (8)
IBD in 2012: Pathogenesis and management of IBD—thinking outside the box (2013) (8)
Selection criteria and outcome of patients referred to intestinal transplantation: an European center experience. (2006) (8)
W1220 Flexibility in Interval and Dosing of Infliximab Enables Maintained Response of Patients with Crohn's Disease (2008) (8)
P494 Elderly patients with inflammatory bowel disease under anti-TNF therapy: efficacy and safety (2014) (8)
Does the biomarker 15N-lactose ureide allow to estimate the site of fermentation of resistant starch? (2008) (8)
Early Trough Levels and Antibodies Predict Safety and Success of Restarting Infliximab After Long Drug Holiday (2011) (8)
Mutations in innate immune receptors modulate the serologic response to microbial antigens in patients with inflammatory bowel disease (2006) (8)
Evolution of Endoscopic Activity Scores in Patients With Crohn's Disease Under Azathioprine and/or Infliximab: A Post-Hoc Analysis of the Sonic Data (2011) (7)
Sustained Steroid-Free Clinical Remission in Patients with Moderate to Severe Crohnʼs Disease Treated with Adalimumab: 1181 (2006) (7)
Distal ulcerative colitis is mostly accompanied by inflammatory lesions of the cecum : results of a prospective endoscopic study (1987) (7)
Ulcerative jejunitis in patients with established ulcerative colitis (1994) (7)
S1030 Predictors of Response and Remission to Certolizumab Pegol in Patients With Crohn's Disease: Data From the WELCOME Study (2010) (7)
Serum S100A12 as a new marker for inflammatory bowel disease and its relationship with disease activity (2010) (7)
Gastric emptying andHelicobacter pylori infection in duodenal ulcer disease (1996) (7)
T1153 Infliximab Treatment for Ulcerative Colitis: Comparable Clinical Response, Clinical Remission, and Mucosal Healing in Patients with Disease Duration < 3 Years Vs ≥ 3 Years (2008) (7)
Quantification of (15)N-nitrate in urine with gas chromatography combustion isotope ratio mass spectrometry to estimate endogenous NO production. (2010) (7)
Malabsorption and motor dysfunction in small bowel amyloidosis - report of two cases and review of the literature (1992) (7)
Esophageal metastasis from breast carcinoma. (1994) (7)
W1096 Results from An Open-Label Extension of CHARM: Steroid-Free Remission in Patients with Crohn's Disease Who Received Adalimumab Therapy for At Least 3 Years (2009) (7)
539 Anti-TNF-Induced Skin Manifestations in IBD Patients: Role for Increased Drug Exposure? (2015) (7)
Measurement of 13C-glucose oxidation rate using mass spectrometric determination of the CO2: Ar ratio and spirometry. (1988) (7)
Gastrointestinal endoscopy and the patient with a risk of bleeding disorder. (1999) (7)
W1382 The Bifidogenic Potential of Arabinoxylo-Oligosaccharides in Healthy Volunteers Depends On the Degree of Polymerisation (2008) (7)
CDP870, a pegylated humanized anti-TNF antibody fragment, offers particular benefit to Crohn's disease patients with elevated C-reactive protein (2003) (7)
Induction Therapy with Certolizumab Pegol in Patients with Moderate to Severe Crohnʼs Disease: A Placebo-Controlled Trial: 1156 (2010) (7)
Malabsorption and motor dysfunction in patients with small bowel amyloidosis. (1994) (7)
Does intercurrent hepatitis have a beneficial effect on the course of Crohn's disease? (1983) (7)
Intravenous cyclosporine (CyA) monotherapy versus intravenous methylprednisolone (MP) monotherapy in severe ulcerative colitis: A randomized, double blind controlled trial (1998) (7)
The effect of long‐term fibre and starch intake by man on faecal bile acid excretion (1988) (7)
Neodymium-Yag laser photocoagulation for haemostasis of gastrointestinal non-variceal haemorrhage. (1983) (7)
The use of SEP-PAKTM C18 Cartridges in the Preparation of Bile Acid Methyl Ester Acetates (1982) (7)
Logistic regression of clinical parameters influencing response to infliximab (2001) (7)
Original ContributionsPatterns of symptoms in functional dyspepsia: role of Helicobacter pylori infection and delayed gastric emptying (1998) (7)
Novel Biological Strategies in Inflammatory Bowel Diseases (2004) (6)
Panel of serologic antibodies in patients with indeterminate colitis (2003) (6)
OC-057 A PH3 Randomised, Multicenter, Double-Blind, Placebo (PBO)-Controlled Study of Ustekinumab (UST) Maintenance Therapy in Moderate–Severe Crohn’s Disease (CD) PTS: Results from IM-UNITI (2016) (6)
Anti-TNF induced skin manifestations in IBD patients : characterization and search for predisposing factors (2011) (6)
Myenteric ganglionitis in unaffected ileal section margins predicts severe and early postoperative Crohn's disease recurrence (2006) (6)
Su2091 Results of a Phase II, Randomized, Double Blind, Controlled Trial of the Efficacy of Active Therapeutic Immunization With TNF-Kinoid in Patients With Moderate to Severe Crohn's Disease With Secondary Resistance to TNFα Antagonist (2012) (6)
Decreased mucosal lymphocyte proliferation following treatment with infliximab in Crohn's disease (2000) (6)
S31 Mucosal healing in Crohn's disease is associated with high infliximab trough levels (2010) (6)
P323 Sustained therapeutic benefit of vedolizumab throughout 1 year in ulcerative colitis in GEMINI I, a randomized, placebo-controlled, double-blind, multicenter trial (2013) (6)
Indeterminate colitis in clinical practice (2003) (6)
Long-term outcome of IBD patients with primary non-response to anti-TNF therapy (2015) (6)
Effects of partial ileocolectomy and Crohn's disease on biliary lipid secretion (1987) (6)
Oral malodor, assessed by closed-loop, gas chromatography, and ion-trap technology (1997) (6)
Endoscopy of the oesophagus (1986) (6)
W1221 Long-Term Efficacy and Safety of Adalimumab Treatment in a Single-Center Cohort of Crohn's Disease Patients Who Failed to Infliximab Treatment (2008) (6)
Infliximab Reduces Colectomy in Patients with Moderate-to-Severe Ulcerative Colitis: Analysis from ACT 1 and ACT 2: 984 (2007) (6)
Determination of deuterated phenylalanine and tyrosine in egg protein by GCQ (1999) (6)
Cyclosporine Monotherapy Is Effective in the Treatment of Severe Ulcerative Colitis (1996) (6)
Induction, Maintenance, and Sustainability of the Healing of Draining Fistulas in Patients with Crohnʼs Disease Treated with Adalimumab: Results of the CHARM Study (2006) (6)
Vaccination and infection prevention in inflammatory bowel disease (2010) (6)
Quality of life improvements in a phase 2 study of natalizumab for active Crohn's disease (2003) (5)
Tauro-7 alpha, 12 alpha-dihydroxy-5 beta-cholanic acid as internal standard in the gas-liquid chromatographic analysis of bile acid methyl ester acetates. (1983) (5)
Continuous Clinical Response Is Associated With a Change of Disease Course in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab. (2018) (5)
Anti-TNF treatment restores the gut barrier in Crohn's disease (2001) (5)
Infliximab (Remicade) maintenance treatment strategy is superior to episodic treatment in patients with Crohn?s disease (2001) (5)
T2026 A Dietary Intervention With Arabinoxylan Oligosaccharides Reduces Colonic Protein Fermentation in Healthy Subjects: Results From Faecal Metabolite Fingerprint Analysis (2010) (5)
P020 Efficacy of a Third Anti-TNF Monoclonal Antibody in Crohn's Disease after Failure of Two Other Anti-TNF (2008) (5)
P300 Health related quality of life results through week 22 from the CERTIFI study, a multicenter, randomized, double-blind, placebo-controlled Phase2b study of ustekinumab in patients with moderately to severely active Crohn's disease (2012) (5)
Impressive histologic improvement after TNF antibody (cA2) therapy in active Crohn's disease (1996) (5)
Endoscopic characteristics of the relapse of Crohn's disease after inflixlmab (RemicadeR) therapy (2000) (5)
The changing face of treatment for Crohn's disease (2006) (5)
Ileoscopy with biopsy versus radiology in the diagnosis of terminal ileitis (1980) (5)
Combination therapy with metronidazole and azathioprine reduces severe postoperative recurrence of Crohn's disease: A double-blind controlled randomized trial (2007) (5)
Natalizumab Maintains Remission for 2 Years in Patients with Moderately to Severely Active Crohnʼs Disease and in Those with Prior Infliximab Exposure: Results from an Open-Label Extension Study (2006) (5)
The role and importance of endoscopic mucosal healing in Crohn’s disease (2004) (5)
923 Infliximab Therapy for Refractory Crohn's Disease (CD) Decreases the Long-Term Need for Bowel Surgery (2008) (5)
Emerging biological treatments in inflammatory bowel diseases. (2006) (5)
Should family members of IBD patients be screened for CARD15/NOD2 mutations? (2008) (5)
Effect of arabinoxylo-oligosaccharides on proximal gastrointestinal motility and digestion in healthy volunteers (2008) (5)
Infliximab Induces and Maintains Mucosal Healing in Ulcerative Colitis Patients: The ACT Trials (2005) (5)
645 Switch to Adalimumab in Patients With Crohn's Disease Controlled by Maintenance Infliximab. the Prospective Randomized Switch Study (2010) (5)
P253 Transient versus sustained antibodies to infliximab: Possibility to overcome low titer antibody responses by dose optimisation (2012) (5)
The RANTES −28 g polymorphism is associated with primary sclerosing cholangitis (2007) (5)
The role of aminosalicylates in the treatment of ulcerative colitis. (2002) (5)
Endoscopy as a diagnostic tool in inflammatory bowel disease. (1989) (5)
RFD7-RFD9 coexpression by macrophages points to T cells. Macrophage interaction deficiency in Whipple's disease (1994) (5)
Adalimumab Safety in Crohnʼs Disease Patients: Open-Label Maintenance Following the Gain and CHARM Trials: 1031 (2007) (5)
Effects of Immunomodulators on the Pharmacokinetics and Efficacy of Golimumab in Patients with Moderately to Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT-SC Induction and Maintenance Studies: 1716 (2013) (5)
5-Aminosalicylate is Not Protective From Neoplasia in Ulcerative Colitis (2013) (5)
P262 Patients with refractory pouchitis receiving adalimumab may avoid permanent ileostomy (2012) (5)
Endoscopic healing induced by infliximab maintenance therapy correlates with long-term clinical response in patients with active Crohns Disease. results of endoscopic substudy of accent 1 (2002) (5)
922 Adalimumab Maintains Long-Term Remission in Moderately to Severely Active Crohn's Disease Through 2 Years (2008) (5)
Infliximab for Severe IV Steroid-Refractory Ulcerative Colitis: Can Infliximab Trough Levels Guide Our Management? (2011) (5)
Positive (co2)-c-14 bile-acid breath test in elderly people (1984) (5)
T1139 The ACT Trials: Incremental Benefit of Second and Third Induction Doses of Infliximab in Patients with Moderately-to-Severely Active Ulcerative Colitis (UC) (2008) (5)
Mo1794 Delayed Response to Golimumab Therapy: UC Patient Characteristics and Long-term Clinical Outcome: Post-Hoc Analyses from the PURSUIT Program (2016) (5)
Sa1743 - Reduced Rates of Crohn's- Related Surgeries, Hospitalizations and Alternate Biologic Initiation with Ustekinumab in the Im-Uniti Study Through 2 Years (2018) (5)
Association of Faecalibacterium Prausnitzii and Disease Activity in Ulcerative Colitis (2011) (5)
Likelihood ratio for Crohn's disease as a function of anti-Saccharomyces cerevisiae antibody concentration. (2010) (5)
Glutamine prevents intestinal permeability changes induced by NSAIDs (1996) (5)
919 Maintenance Q8 Therapy of Crohn's Disease with Infliximab Is Associated with Endoscopic Mucosal Healing in the Long-Term (2008) (5)
Infliximab induces death of human monocytes in vitro and in the Thp-1-scid-mice model (2003) (4)
Anti –-enolase Antibodies in Patients with Inflammatory Bowel Disease (2008) (4)
90 Safety and Efficacy of Laquinimod in Inducing Clinical and Biochemical Improvement in Active Crohn's Disease: Results of an Exploratory Trial (2013) (4)
Transient granulomatous aphthoid esophageal lesions in Crohn's disease (1983) (4)
P067 Natalizumab Induces Sustained Response and Remission in Crohn's Patients With Previous Infliximab Failure: Results From The Encore Trial (2007) (4)
9 Assessment of Certolizumab Pegol in the Treatment of Crohn's Disease in Patients for Whom Infliximab Treatment was not Successful: Open-Label Induction Preliminary Results from the Welcome Study (2008) (4)
Are systemic inflammatory markers useful in the prediction of response to infliximab in Crohn's disease? (2001) (4)
A fully human anti-TNF mAb adalimumab (D2E7) induces caspase-dependent apoptosis of human peripheral blood monocyte and T cells (2004) (4)
Safety and efficacy of a novel IV targeted pegylated liposomal prednisolone product (Nanocort): results from a phase 2a study in patients with active ulcerative colitis (2016) (4)
P002 Adalimumab Maintains Long-Term Remission in Crohn's Disease through 2 Years (2008) (4)
Association of Steroid-Free Clinical Remission and Complete Mucosal Healing at 6 Months With Clinical Outcome at 1 Year: A Post-Hoc Analysis of SONIC trial Data (2011) (4)
Gastric Emptying in Renal Failure Patients Using the 13C-Octanoic Acid Breath Test: Facts and Artifacts (2002) (4)
Evidence that glioma-associated oncogene homolog 1 is not a universal risk gene for inflammatory bowel disease in Caucasians (2010) (4)
Mechanisms of probiotic-host interaction with IBD as a case study: a role for exopolysaccharides? (2007) (4)
P404 Predictors of long-term relapse-free and colectomy-free survival in patients with ulcerative colitis treated with infliximab (2013) (4)
Intestinal Epithelial Cells and Innate Immunity in the Intestine: Is CARD15/Nod2 Another Player? (2003) (4)
S1188 Protein Microarray Experiments for Profiling of the Autoimmune Response in Inflammatory Bowel Disease; Identification of PHLA1 (2008) (4)
Diagnostic value of ASCA (anti-saccharomyces cerevisiae antibodies) and pANCA (perinuclear antineutrophil cytoplasmic antibodies) in inflammatory bowel disease (2000) (4)
Tu1286 Early Therapeutic Drug Monitoring for Prediction of Short-Term Mucosal Healing in Patients With Ulcerative Colitis Treated With Infliximab (2015) (4)
Mo1179 Efficacy and Safety of Anti-TNF Therapy in Elderly Patients With Inflammatory Bowel Disease (2014) (4)
Gastric-emptying rate of solids during recovery from hyperemesis gravidarum, using the 13c-octanoic acid breath test (1994) (4)
Efficacy of Ustekinumab for Induction and Maintenance of Histological Healing in patient's with Crohn’s Disease (2017) (4)
Surgical repair of rectovaginal fistula in Crohn’s disease: analysis of prognostic factors (2001) (4)
Breath tests in Helicobacter pylori infection: methodological aspects. (1997) (4)
Lymphocyte Interactions with Smooth Muscle Cells and Nerves (1990) (4)
Immunoreactivity of alpha-1-antitrypsin in the human colon. (1983) (4)
The Value of a Central Image Management System (CIMS) in the Conduct of Randomized Controlled Trials of Therapy for Ulcerative Colitis (UC): 1454 (2012) (4)
13CO2 breath tests and stable isotopes for investigating gastrointestinal functions. (2000) (4)
Risk Factors for Relapse and Recurrence of Ulcerative Colitis and Crohn’s Disease (1993) (4)
GPR84 inhibition as a novel therapeutic approach in IBD: mechanistic and translational studies (2015) (4)
Long-Term Efficacy of Vedolizumab Therapy for Crohn’s Disease: Presidential Poster: 1619 (2014) (4)
Sa1203 Pharmacokinetics and Exposure-Response Relationship of Golimumab in Patients With Moderately to Severely Active Ulcerative Colitis: Results From Phase2/3 Induction and Maintenance Studies (2013) (4)
Certolizumab pegol in the treatment of Crohn's disease (2013) (4)
The Role of FC Gamma Receptor (FCGR) Mutations in the Response to Infliximab in Inflammatory Bowel Disease (2011) (4)
Budesonide Enemas for Topical Therapy of Ulcerative Colitis (1990) (4)
Gastric-emptying rate of solids in non-dyspeptic pregnant-women using the c-13-octanoic acid breath test (1993) (4)
Certolizumab pegol in patients with Crohnʼs disease who failed treatment with other anti-TNFs: data from a compassionate use program: P-065. (2008) (4)
Reduction in neutrophil and not lymphocyte count is associated with favourable response to azathioprine therapy in refractory Crohn's disease (1995) (4)
Effect of disease duration on 'deep remission': Results from the EXTEND trial (2010) (4)
Genetic-wide scanning in a Belgian IBD population reveals novel linkages and validates previous linkages (2001) (4)
Gastric-emptying in distal gastrectomy is characterized by an early dumping of the oil phase compared to normal healthy-volunteers (1994) (4)
UEG Week 2016 Poster Presentations (2016) (4)
Long-Term Efficacy and Safety of Ustekinumab for Crohn’s Disease: Results From Im-Uniti Long-Term Extension Through two Years (2017) (4)
Fine mapping a susceptibility locus on the X chromosome in the Belgian population in inflammatory bowel disease (IBD) (1999) (4)
Two and four mg/kg/day of intravenous cyclosporine are equally effective in severe attacks of ulcerative colitis (2000) (4)
ASCA and panca do not predict response to anti-TNFA (Remicade®) treatment (2000) (4)
Crohn's disease and pre-aphthoid lesions. (1993) (4)
Comparative study on the in vivo efficacy of metronidazole, aztreonam and amoxycillin/clavulanic acid in the indomethacin model: Evidence for immuno-modulatory properties of metronidazole (2000) (4)
P021 SUBCUTANEOUS CERTOLIZUMAB PEGOL IS WELL TOLERATED BY PATIENTS WITH ACTIVE CROHN'S DISEASE: RESULTS FROM TWO PHASE III STUDIES (PRECISE 1 AND 2) (2007) (4)
P229 The modified postoperative endoscopic recurrence score for Crohn's disease: Does it really make a difference in predicting clinical recurrence? (2017) (4)
Vedolizumab Induction Therapy for Patients With Crohn’s Disease and Prior Anti‐TNF Antagonist Failure: A Randomized, Placebo‐controlled, Double‐blind, Multicenter Trial: P‐26 (2012) (4)
498 Adalimumab Trough Serum Levels and Clinical Response in a Single-Center Cohort of Inflammatory Bowel Disease Patients: Can Trough Serum Levels Serve As a Predictor for Future Loss of Response? (2008) (3)
Challenges in Crohn's disease. (2004) (3)
Su1204 Long-Term Outcome of Infliximab Therapy in Patients With Ulcerative Colitis: Identification of Predictors of Relapse-Free and Colectomy-Free Survival (2013) (3)
W1383 The Effect of Two Different Doses of Arabinoxylo-Oligosaccharides and Oligofructose Enriched Inulin On the Colonic Ammonia Metabolism in Healthy Volunteers (2008) (3)
Maintenance therapy with natalizumab improves quality of life in patients with Crohn's disease (2005) (3)
MAINTENANCE AND PROPHYLACTIC THERAPY FOR CROHN'S DISEASE (1997) (3)
Positron emission tomography (PET) compared to EUS & spiral CT in staging of patients with potentially operable esophageal carcinoma (2000) (3)
S1064 Certolizumab Pegol Effectiveness in Crohn's Disease Patients with Secondary Failure to Infliximab Is Independent of Infliximab Dosing: Results from the WELCOME Study (2009) (3)
187 Bacterial Dysbiosis in Ulcerative Colitis Patients Differs From Crohn's Disease Patients (2012) (3)
Determination of urinary methylmalonic acid in urine by gas chromatography with an ion-trap detector, chemic ionization and isotope dilution (1991) (3)
P-057 Reliability of Central Readers in the Evaluation of Endoscopic Disease Activity in Crohn’s Disease (2013) (3)
T1142 Infliximab Treatment for Ulcerative Colitis: Clinical Response, Clinical Remission, & Mucosal Healing in Patients with Moderate or Severe Disease in the Active Ulcerative Colitis Trials (ACT1 & ACT2) (2008) (3)
Study on DLG5 and OCTN polymorphisms shows association of the OCTN to risk haplotype with perianal and fistulizing Crohn's disease but not with susceptibility to IBD (2005) (3)
Mo1880 Mucosal Healing and Dysplasia Surveillance in a Large Referral Center Cohort of Patients With Crohn's Disease and Ulcerative Colitis Treated With Vedolizumab (2016) (3)
Genetic markers and the risk of complicated disease behaviour in Crohn's disease patients (2008) (3)
Tu1106 Observer Agreement and Construct Validity in Central Endoscopic Assessment of Disease Activity in Ulcerative Colitis (2013) (3)
No evidence for linkage on chromosomes 16-12-7 and 3 in the belgian population may reflect genetic heterogeneity of inflammatory bowel disease (1998) (3)
S1058 Certolizumab Pegol Improves Health-Related Quality of Life in Crohn's Disease Patients for Whom Infliximab Treatment Was Not Successful: Results from the WELCOME Study (2009) (3)
Clinical Response Is a Meaningful Endpoint in Ulcerative Colitis Clinical Studies: P‐30 (2012) (3)
Combination therapies for the endoscopic treatment of gastrointestinal bleeding. (2000) (3)
Regain of Response and Remission by Dose Adjustment in Patients with Crohnʼs Disease Who Responded to Certolizumab Pegol: Results from the WELCOME Study: 1214 (2009) (3)
OC-005 A Multicenter, Double-Blind, Placebo (PBO)-Controlled Ph3 Study of Ustekinumab (UST), A Human IL-12/23P40 MAB, in Moderate-Severe Crohn’s Disease (CD) Refractory to anti-TNFΑ: UNITI-1 (2016) (3)
The value of ileal biopsies in the diagnosis of IBD (1995) (3)
O-003 YI Drug Level Versus Clinically Based Dosing of Infliximab Maintenance Therapy In IBD: Final Results of the Randomized Controlled Taxit Trial (2013) (3)
High dose ropivacaine treatment in active distal ulcerative colitis induces a global reduction of histological inflammation (1997) (3)
Endoscopic contact Nd-YAG laser therapy for colorectal cancer: a randomized comparison with non-contact therapy (2007) (3)
Natalizumab decreases inflammatory cells within the colonic lamina propria of patients with active Crohn's disease: results from ENACT-1 (2004) (3)
P128 The value of a central image management system (CIMS) in the conduct of randomized controlled trials of therapy for ulcerative colitis (UC) (2013) (3)
A follow-up study of self-expandable barbell-shaped metallic stents in the palliation of rectosigmoidal carcinoma (1996) (3)
13C-breath tests in peritoneal dialysis patients: influence of dialysis fluids. (2003) (3)
The role of radiology in Campylobacter enterocolitis. (1989) (3)
DOP073 Efficacy of induction treatment with vedolizumab for patients with Crohn's disease who have experienced tumour necrosis factor antagonist failure or are tumour necrosis factor antagonist naive (2014) (3)
W1092 Maintenance of Long-Term Remission in Patients with Moderately to Severely Active Crohn's Disease Treated for 3 Years with Adalimumab: Results from the Open-Label ADHERE Study (2009) (3)
Urea breath test in helicobacter-pylori infected subjects is influenced by gastric-emptying rate (1994) (3)
Treatment of Achalasia: Pneumatic Dilation (1990) (3)
OC-007 A Multicenter, Double-Blind, Placebo (PBO)-Controlled Ph3 Study of Ustekinumab (UST), A’Human MAB to IL-12/23P40, IN PTS with Moderately-Severely Active Crohn’s Disease (CD) Who are Naïve or not Refractory to anti-TNFΑ: UNITI-2 (2016) (3)
Long term evolution and impact of immunomodulator cotreatment and withdrawal on infliximab on trough levels in 223 patients with Crohn's disease (2011) (3)
Microscopic Barrett's esophagus: relationship to acid and bile reflux in man (1998) (3)
P088 COLECTOMY RATES AFTER INFLIXIMAB FOR REFRACTORY ULCERATIVE COLITIS AND PREDICTIVE FACTORS (2007) (3)
Prevention of duodenal ulcer recurrence by pirenzepine 50 mg twice daily. (1987) (3)
Book Review Gastrointestinal Pharmacology & Therapeutics Edited by Gerald Friedman, Eugene D. Jacobsen, and Richard W. McCallum. 780 pp., illustrated. Philadelphia, Lippincott–Raven, 1997. $159. 0-397-51625-8 (1997) (3)
Sustained Therapeutic Benefit of Vedolizumab Throughout 1 Year in Ulcerative Colitis in GEMINI I, a Randomized, Placebo‐Controlled, Double‐Blind, Multicenter Trial: O‐1a (2012) (3)
AGA AbstractsW1244 Efficacy of a Third Anti-TNF Monoclonal Antibody in Crohn's Disease After Failure of Two Other Anti-TNF (2008) (3)
Efficacy and safety of rioprostil, 300 micrograms b.d., in the treatment of gastric ulcer: a comparison vs. ranitidine, 150 mg b.d., in a randomized multicentre study. (1989) (3)
Clinical improvement precedes mucosal healing in ulcerative colitis treated with anti-IL-2-agents (2002) (3)
Clinical Outcomes in Continuous Clinical Responders with Moderately to Severely Active Ulcerative Colitis: Subanalyses from the PURSUIT-SC Maintenance Study: 1709 (2014) (3)
Natalizumab Does Not Require the Concomitant Use of Immunosuppressants or Corticosteriods for the Induction of Sustained Response and Remission in Patients with Crohnʼs Disease: 1025 (2007) (3)
Infliximab does not increase postoperative complication rates in patients with Crohn's disease (2003) (3)
P217 - Genetic variants in autophagy related genes and granuloma formation in patients with Crohn's disease (2009) (3)
Postinfectious irritable bowel syndrome: a genetic link identified? (2010) (3)
Endoscopic treatment of peptic ulcer bleeding (1988) (3)
The destruction of the autonomic nervous system in Crohn's disease is due to immunologic effector cells (1989) (3)
Basic fibroblast growth factor (BFGF) as a response parameter to infliximab (Remicade)in fistulizing Crohn's disease (2003) (3)
Evidence for malabsorption and increased colonic fermentation of protein, related to gastric acid suppression therapy (1997) (3)
Study of protein assimilation, using stable isotope techniques. (1998) (3)
Vascular malformations of the colon (1984) (3)
Quality-of-life Improvements in Adalimumab-treated Patients with Mucosal Healing: Results from the EXTEND Trial: 1237 (2009) (3)
P386 Pharmacokinetics of laquinimod in patients with active moderate to severe Crohn's disease (2014) (3)
Persistent fistula tracks in perianal Crohn's disease after long term infliximab treatment: Correlation with clinical outcome (2003) (3)
T1795 Impaired Butyrate Oxidation in Ulcerative Colitis is Due to Decreased Butyrate Uptake and a Defect in the Oxidation Pathway (2010) (3)
Can we prevent the inevitable? The use of 6-mercaptopurine or mesalamine to prevent postoperative recurrence in patients with Crohn disease (2005) (3)
Effects of Infliximab Therapy on Transmural Lesions Assessed by MRI Enteroclysis in Patients With Ileal Crohn's Disease: The ACTIF Study (2011) (3)
Are section margins useful for the prediction of recurrence of Crohn's disease after all? (1990) (3)
M2064 Development of Psoriasiform Skin Lesions Under Anti-TNF Therapy: A Common Link with IL23R Gene Variants? (2008) (3)
Adalimumab Efficacy and Safety by Disease Duration: Analysis of Pooled Studies of Crohn's Disease (2017) (3)
A prospective randomised trial comparing three hemostasis modalities for bleeding peptic ulcers: Injection therapy with epinephrin and polidocanol 1% versus hemoclip versus injection combined with hemoclip and interim report (1997) (3)
Reply to selected summary: To cut is not to cure (Gastroenterology 1985;88:1280–1281) (1985) (2)
OP010 AlphaE integrin expression as a predictive biomarker for induction of clinical remission by etrolizumab: Analysis of a phase II trial in moderate-to-severely active ulcerative colitis (2014) (2)
P068 Natalizumab Maintains Remission For 2 Years in Patients With Moderately to Severely Active Crohn's Disease and in Those With Prior Infliximab Exposure: Results From an Open-Label Extension Study (2007) (2)
A Randomized Placebo-Controlled Trial of Infliximab Therapy for Active Ulcerative Colitis: ACT I Trial Results through Week 54 (2005) (2)
Orocaecal transit time: The lactose-C-13-ureid breath test shows a good correlation with scintigraphy (1997) (2)
Double deconvolution of breath tests to assess the pharmacological modulation by cisapride of proximal gastrointestinal transit (1999) (2)
995 Feasibility, Precision and Reproducibility of MR Enterography for Detection of Inflammation in Crohn's Disease in a Multicenter Clinical Trial (2014) (2)
Su1745 Characterization of Molecular Response to Golimumab in Ulcerative Colitis by mRNA Expression Profiling: Results From Pursuit-SC Induction Study (2013) (2)
P113 Short-Term Adalimumab Therapy Improves Quality of Life in Patients Who had Failed Infliximab Therapy: Results From the Gain Trial (2007) (2)
Interstitial thermotherapy for liver tumours: Studies of different fibres and radiation characteristics (1993) (2)
A sham-controlled study of the influence of radiofrequency delivery (the Stretta procedure) on symptoms, acid exposure and distentibility of gastro-oesophageal junction in GORD patients (2006) (2)
S1063 Sustained Improvement in Quality of Life for Patients with Fistulizing Crohn's Disease Treated with Adalimumab: 3-Year Data from CHARM (2009) (2)
Budesonide is effective in collagenous colitis: a prospective double blind placebo controlled trial with histologic follow-up (2001) (2)
Infliximab Reduces Endoscopic, but not Clinical, Recurrence of Crohn’s Disease Following Ileocolonic Resection (2016) (2)
Postoperative prevention of recurrence of Crohn’s disease (2003) (2)
Lactulose administration in healthy volunteers is associated with a reduced b-glucuronidase activity and an increase in fecal bifidobacteria (2005) (2)
864 Efficacy of Vedolizumab Induction Therapy in Patients With Crohn's Disease Who Have Experienced Tumor Necrosis Factor Antagonist Failure or Are Tumor Necrosis Factor Antagonist Naive (2014) (2)
P186 Outcomes of maintenance ustekinumab therapy for Crohn’s disease based on inflammatory burden: A post-hoc analysis of the UNITI trials (2018) (2)
The value of anti-Saccharomyces cerevisiae antibodies (ASCA) as subclinical marker in Crohn's disease (CD) (1999) (2)
Clinical risk factors determining recurrence in Crohn's disease. (1996) (2)
W1132 A 3-Week Course of 80 Mg Weekly Administered Adalimumab As a Rescue Therapy for Patients with Crohn's Disease Who Lost Response to 40 Mg Weekly: Relationship with Adalimumab Trough Serum Levels (2008) (2)
1000 Agreement Among Central Readers in the Evaluation of Endoscopic Disease Activity in Crohn's Disease (2014) (2)
Comparison of endorectal ultrasound and CT-scan in the preoperative staging of colorectal cancer (1998) (2)
Correlation of ileal emptying and gastric emptying calculated from a simultaneous application of two breath tests (1998) (2)
Immortal time bias and infliximab-related mortality and malignancy incidence (2010) (2)
Tu1932 Mucosal Gene Expression Differences Between Early and Post-Operative Recurrent/Late Ileal Crohn's Disease Suggest Increased Inflammatory Load in Early Disease (2012) (2)
The use of the neurokinin-1 receptor antagonist, SR-140333B, nolpitantium besilate, in mild to moderate active ulcerative colitis (2003) (2)
DOP044 Relationship between microbiota and development of early postoperative Crohn's disease recurrence. (2017) (2)
91 Sustained Therapeutic Benefit of Vedolizumab Throughout 1 Year in Crohn's Disease in Gemini II, a Randomized, Placebo-Controlled, Double-Blind, Multicenter Study (2013) (2)
THE FULL PICTURE OF ULCERATIVE COLITIS : THE BURDEN , THE PATIENT , THE TREATMENT This symposium took place on 26 th October 2015 as part of United European Gastroenterology ( UEG ) Week 2015 in Barcelona , Spain (2015) (2)
Magnification imaging in inflammatory bowel disease: a useful aid for the prediction of disease relapse? (2006) (2)
Infliximab for pediatric Crohn's disease. (2008) (2)
OP006 Correlation of durability of response, serum trough concentrations and outcome parameters: long-term follow-up of the Trough Concentration Adapted Infliximab Treatment (TAXIT) trial. (2017) (2)
Su1168 Neutrophil Gelatinase B-Associated Lipocalin - Matrix Metalloproteinase-9 (NGAL-MMP-9) Complex As a Surrogate Serum Marker for Mucosal Healing in Ulcerative Colitis (2013) (2)
Su1276 αE Integrin Expression As a Predictive Biomarker for Induction of Clinical Remission by Etrolizumab: Analysis of a Phase II Trial in Moderate-to-Severely Active Ulcerative Colitis (2014) (2)
Long-Term Efficacy of Ustekinumab With and Without Concomitant Immunosuppressants for Crohnʼs Disease: Results From IM-UNITI Long-Term Extension Through 2 Years (2018) (2)
Su1220 Rectal Bleeding Accurately Reflects Level of Mucosal Inflammation in Patients With Ulcerative Colitis (2015) (2)
Impact of Golimumab SC on Disease Specific and Generic HRQoL in Patients With Moderately to Severely Active UC: PURSUIT‐SC Induction: P‐69 (2012) (2)
Early and Sustained Remission after Treatment with Subcutaneously Administered Golimumab Is Associated with Normalized Health-Related Quality of Life in Patients with Moderate to Severe Ulcerative Colitis: Post-hoc Analysis from PURSUIT Induction and Maintenance Trials: 1721 (2013) (2)
Adverse skin reactions to anti-TNF agents : a systematic review of a single center cohort (abstract) (2007) (2)
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2b Study of Ustekinumab, a Human Monoclonal Antibody to Il-12/23p40, in Patients with Moderately to Severely Active Crohnʼs Disease: Results through Week 36 from the CERTIFI Trial: 2011 ACG Presidential Poster: 1227 (2011) (2)
Mannan-binding lectin gene polymorphisms in ulcerative colitis and Crohn's disease (2001) (2)
P225 Impact of subcutaneously administered golimumab on disease specific and generic health-related quality of life in patients with moderately to severely active ulcerative colitis: Results from PURSUIT-SC induction (2013) (2)
Role of Haptoglobin in Susceptibility of IBD and in Triggering Murine Colitis (2011) (2)
CD44v6 and CD44v3 variants in inflammatory bowel disease (1995) (2)
Continuous vs. Induction Only/Reinitiated Adalimumab Maintenance Therapy Yields Optimal Results for Moderate to Severe Crohn's Disease: Subanalysis of CHARM: 922 (2007) (2)
ABT-229, a new motilin agonist, increases gastric emptying of solids in man (1996) (2)
Clinical response to Infliximab is associated with a substantial increase in quality of life (2000) (2)
Permeability for water soluble macromolecules is increased in macroscopically normal jejunal mucosa of patients with Crohn's disease (1991) (2)
493 Safety Profile and Signal of Efficacy of a Non-Fcr-Binding, Fully Human Anti-Cd3 Monoclonal Antibody in Patients with Moderate to Severe Crohn's Disease- Results of a Phase I/Iia, Double Blind, Placebo-Controlled, Randomized, Dose Escalation Study (2008) (2)
Vasculitis and Crohn's disease (1995) (2)
Mo1215 Serum Golimumab Exposure and the Incidence of Selected Safety Events in Patients With Ulcerative Colitis Following Treatment With Golimumab: An Exploratory Analysis of the PURSUIT Study Data (2014) (2)
Comparative study of low power neodymium-YAG laser interstitial hyperthermia versus ethanol injection for controlled hepatic tissue destruction (2005) (2)
Postoperative recurrence of Crohn's disease: pathogenesis and prevention. (1994) (2)
P142 Subcutaneously administered golimumab induction therapy improves health states measured by EQ-5D in patients with moderately to severely active ulcerative colitis: results from PURSUIT-SC (2013) (2)
[Drug prevention of Crohn disease recurrence in the neo-terminal ileum after ileocolic resection]. (1998) (2)
999 In Vitro and In Vivo Characterization of Neutralizing Monoclonal Antibodies Against Clostridium difficile Toxins a and B (2013) (2)
ASCA (anti-saccharomyces cerevisiae antibodies) in healthy relatives of sporadic and familial Crohn's disease patients (2001) (2)
What can we expect from endoscopic dilation of the stenotic tract in Crohn's disease? (2008) (2)
Current dilemmas in the management of inflammatory bowel disease. (2002) (2)
Early lesions of recurrent Crohnʼs disease caused by infusion of intestinal contents in excluded ileum (1998) (2)
Monoclonal IL-10 therapy decreases ileocolonic inflammation in Crohn's disease (1996) (2)
Gastro-intestinal effects of different doses of arabinoxylanoligosaccharides in healthy volunteers: gastric emptying, oro-caecal transit time, total transit and H2-excretion (2006) (2)
Mucosal distribution of infliximab in patients with Crohn's disease (CD) (2001) (2)
Su1394 Prediction of Sustained Remission After Discontinuation of Infliximab in Patients With Crohn's Disease (2014) (2)
Mo1230 Systematic Versus Endoscopy-Driven Treatment With Azathioprine to Prevent Postoperative Ileal Crohn's Disease Recurrence: Interim Results From a Randomized, Multicenter Trial (2014) (2)
Remission of severe ulcerative colitis with cyclosporine monotherapy is effectively maintained with further immunosuppression (1999) (2)
A panel of anti-glycan antibodies (gASCA, ALCA, ACCA and AMCA) in the diagnosis and differential diagnosis of IBD (2006) (2)
Chemokine receptor CCR5 Δ32 gene polymorphism in Crohn's disease and ulcerative colitis (2000) (2)
Push enteroscopy has a higher yield for the diagnosis of the source of occult bleeding than sonde-type enteroscopy (1994) (2)
Neodymium-Yag laser treatment of gastrointestinal angiomas (1983) (2)
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous Golimumab Maintenance Therapy in Patients with Moderately to Severely Active Ulcerative Colitis: PURSUIT-Maintenance: 1665 (2012) (2)
ADALIMUMAB, A HUMAN ANTI-TNF-α MONOCLONAL ANTIBODY, INDUCES CLINICAL REMISSION AND RESPONSE IN PATIENTS WITH MODERATE TO SEVERELY ACTIVE CROHNʼS DISEASE IRRESPECTIVE OF SMOKING STATUS: 800 (2004) (2)
A Treat to Target Approach Decreases the Rate of CD-Related Adverse Outcomes versus a Clinical Approach in Patients With Moderate to Severely Active Crohnʼs Disease: Data From CALM 2017 ACG Governors Award for Excellence in Clinical Research: 598 (2017) (2)
In vitro analysis of IGN-gamma and IL-12 production and their effects in ileal Crohn’s disease (2003) (2)
Gastric digestion plays a substantial role in normal protein assimilation (1996) (2)
Tu1723 – Identification of Risk Factors Associated with Loss of Response to Ustekinumab in Crohn's Disease (2019) (2)
ASCA and PANCA prevalence in mixed-IBD families (1999) (2)
Certolizumab Pegol Is Efficacious in Crohnʼs Disease Patients Who Have Failed Infliximab Regardless of Concomitant Therapy or Reason for Failure: 1103 (2008) (2)
Radiofrequency delivery (the Stretta procedure) reduces the distensibility of the gastro-esophageal junction in GERD patients (2005) (2)
Assessment of theMicrobiota inMicrodissected Tissues of Crohn ’ s Disease Patients (2014) (2)
P676 Primary response to infliximab in Crohn's disease is associated with the TNFRSF1A rs1800693 gene polymorphism (2013) (2)
Egg protein assimilation in pancreatic disease studied with a C-13 egg white breath test (1996) (2)
16 Relationships between clinical remission, C-reactive protein normalization and mucosal healing in Crohn's disease: analyses from the SONIC trial (2013) (2)
OP009 Long-term safety and efficacy of golimumab in patients with moderately to severely active ulcerative colitis: Results from the PURSUIT-SC Maintenance study extension (2014) (2)
The evolution of fatigue in patients with Crohn's disease after treatment with infliximab: A prospective study (2004) (2)
A polymorphism in IgG Fc receptor gene FCGR3A is associated with biological response to infliximab in crohn disease (2003) (2)
Use of naturally 13C-enriched substrates for the study of carbohydrate and protein assimilation by means of 13CO2-breath tests (1988) (1)
Infliximab (anti-TNF antibody) induces histologic remission without increase of epithelial cell proliferation (1999) (1)
Analysis of the direct cost generated by infliximab (RemicadeR) to normalize quality of life in patients with Crohn's disease (2001) (1)
Gastric-emptying of solids and nonulcer dyspepsia (1995) (1)
Infliximab treatment results in the sustained reduction of inflammatory markers in the mucosa of patients with Crohns disease (2002) (1)
Safety of Adalimumab in Global Clinical Trials of Patients with Crohnʼs Disease: 1142 (2010) (1)
(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC): successful treatment of a patient with disseminated esophageal and hypopharyngeal papillomatosis (1994) (1)
Vascular endothelial growth factor (VEGF) polymorphisms are implicated in susceptibility to IBD (2005) (1)
Work Productivity Improvements in Adalimumab-treated Patients with Moderate to Severe Ileocolonic Crohnʼs Disease: The EXTEND Trial: 1238 (2009) (1)
Endoscopic Healing in Induction and Maintenance with Ustekinumab in the Phase 3 UNITI Crohnʼs Disease Program: 2016 ACG Presidential Poster Award: 605 (2016) (1)
T1209 New Mechanism of Action for Anti-TNF Therapy in IBD: Induction of FOXP3+CD4+CD25+ and FOXP3+CD4+CD25- T Cells in Crohn's Disease and Ulcerative Colitis (2008) (1)
A potential role of interleukin 15 in T cell activation in inflammatory bowel disease (1999) (1)
A faster gastric emptying rate during reconvalescence of hyperemesis gravidarum strongly correlates with thyroidal function (1996) (1)
Ranst Analysis of the CC chemokine receptor 5 ( CCR 5 ) delta-32 polymorphism in inflammatory bowel disease (1)
Sa1734 - Impact of Prior Surgical History on Efficacy with Ustekinumab in Crohn's Disease: A Subgroup Analysis of the Phase 3 Uniti Studies (2018) (1)
Transmission ratio distortion of DLG5 R30Q: evidence for prenatal selection? (2010) (1)
Direct demonstration of the effect of lactulose on colonic bacterial metabolism by application of lactose-(15N)-ureide (1998) (1)
The effect of two different types of arabinoxylanoligosaccharides on the level of human faecal bifidobacteria determined using real-time PCR (2006) (1)
Influence of resistant starch with or without wheat bran on p-cresol: short and long term effects (2005) (1)
Poster PresentationsP060 CORTICOSTEROIDS POSE AN INCREASED RISK FOR SERIOUS INFECTION: AN INTERIM SAFETY ANALYSIS OF THE ENCORE REGISTRY (2008) (1)
P096 Analysis of the tryptophan metabolism and indoleamine 2,3-dioxygenase expression (IDO) in patients with inflammatory bowel disease before and after infliximab treatment (2014) (1)
1103 Predictive Value of C-Reactive Protein Level Changes On the Long Term Outcome of Infliximab in Crohn's Disease (2009) (1)
T1138 Global Safety of Adalimumab in Crohn's Disease Clinical Trials (2008) (1)
Su1240 Comparison of Rectosigmoidoscopy and Colonoscopy for Assessment of Endoscopic Activity in Ulcerative Colitis (2015) (1)
STUDY ON CARD15 AND TLR4 POLYMORPHISMS IN CHILDREN WITH EARLY DIAGNOSED IBD: PG2-02 (2005) (1)
Depressed T cell reactivity to recall antigens in Crohn's disease before and after surgical resection. (1994) (1)
The fasting bile-acid pool size is not equal to the circulating pool size (1981) (1)
P148 - Adalimumab maintains long-term remission in patients with moderately to severely active Crohn's disease through 3 years of therapy (2009) (1)
W1228 Genes Associated With Reduced Epithelial Permeability and Epithelial-Mesenchymal Transition: Changes in Expression Following Infliximab Therapy in Ulcerative Colitis (2010) (1)
PGI16: ANALYSIS OF THE LONG-TERM COSTS, SAVINGS AND EFFECTS GENERATED BY INFLIXIMAB TO NORMALIZE QUALITY OF LIFE IN PATIENTS WITH CROHN'S DISEASE (2001) (1)
Short-term response to infliximab in ulcerative colitis and pouchitis: Results from a single-center experience (2006) (1)
M1047 Quality-of-Life Benefits for Adalimumab-Treated Patients With Moderate to Severe Crohn's Disease are Predicted by Early Mucosal Healing Status (2010) (1)
Correlation of Durability of Response, Serum Trough Concentrations and Outcome Parameters: Long-Term Follow-up of the Trough Concentration Adapted Infliximab Treatment (TAXIT) Trial (2017) (1)
Achievement of early deep remission predicts better long-term outcomes for adalimumab-treated patients with Crohn's disease (2011) (1)
Proinflammatory effects of IL-10 in pathological ileal Crohn's disease (1999) (1)
Increased proinflammatory cytokine production in macroscopically normal ileum and colon in crohns-disease (1995) (1)
Diminshed sensitivity of ileal lamina propria mononuclear cells to the inhibitory effect of IL-10 in Crohn's disease (1998) (1)
Tu1343 Long-Term Outcome of IBD Patients With Primary Non-Response to Anti-TNF Therapy (2015) (1)
The MDR1 G2677T polymorphism is associated with gastrointestinal intolerance to azathioprine (2006) (1)
DNA polymorphism in the human motilin gene in inflammatory bowel disease (1997) (1)
Comparison of the effect of long-term administration of OF-IN ingested in combination with Lactobacillus casei Shirota or OF-IN alone on the colonic fate of protein fermentation metabolites NH3 and phenols (2006) (1)
The TNFα-308∗2 allele predicts non-response to remicade® (2000) (1)
DLG5 R30Q does not predict response to infliximab therapy in Hungarian patients with Crohn's disease (2006) (1)
Drug induced recurrent chronic gastric and small bowel ulcers: an x-ray spectroscopy analysis of mucosal biopsies (1989) (1)
Are collagenous and lymphocytic colitis one disease? A histologic analysis of 178 cases (1998) (1)
The protease genes CYLD and USP40 are associated with Crohn's disease: results from a European Consortium (2011) (1)
Su1793 - Outcomes of Maintenance Ustekinumab Therapy for Crohn's Disease Based on Inflammatory Burden: A Post-HOC Analysis of the Uniti Trials (2018) (1)
Immunogenicity of Natalizumab in Crohnʼs Disease Following Continuous or Interrupted Dosing: 1143 (2006) (1)
Re-defining outcomes and re-evaluating remission in in fl ammatory bowel disease : Assessing key evidence (2008) (1)
GIVEN® PATENCY SYSTEM IS A NEW DIAGNOSTIC TOOL FOR VERIFYING FUCTIONAL PATENCY OF THE SMALL BOWEL: 188 (2004) (1)
P275 Clinical response is a meaningful endpoint in ulcerative colitis clinical studies (2013) (1)
Health related quality of life results through week 22 from the CERTIFI study, a multicenter, randomized, double-blind, placebo-controlled phase2b study of Ustekinumab in patients with moderately to severely active Crohn's diseaseP-39. (2011) (1)
A20/TNFAIP3 as a brake on intestinal inflammation and tumorigenesis (2014) (1)
Infliximab: the evidence for its place in therapy in ulcerative colitis (2008) (1)
Tu1748 Predominant Gut Microbiota Predict Pouchitis Following Colectomy and IPAA in Ulcerative Colitis (2014) (1)
HLA-DRB1 and the Development of Antibodies to Infliximab in Inflammatory Bowel Disease (2013) (1)
Osteoblast function is suppressed by oral methylprednisolone but not by budesonide CIR in active ileocolonic Crohn's disease (1996) (1)
Sa1956 Post-Induction Adalimumab Concentration Threshold Is Associated With Short-Term Mucosal Healing in Patients With Ulcerative Colitis (2016) (1)
DOP063 Biomarker panel for prediction of mucosal healing in patients with Crohn's disease under infliximab therapy (2014) (1)
Influence of genetics in the expression of serological markers in twins with IBD (2012) (1)
P067 Molecular profiling of early Crohn's disease reveals a prominent role for WNT5A. (2017) (1)
P114 Adalimumab Safety in Crohn's Disease: A Sub-Analysis of Immunosuppressant and Steroid Use in the Charm Trial (2007) (1)
Intestinal microbial signature predicts postoperative Crohn's disease recurrence following ileocaecal resection with ileocolonic anastomosis (2015) (1)
Differential effect of resistant starch type 2 and type 3 on gastric emptying and protein digestion in healthy volunteers (2005) (1)
Short term and long term study of oligofructose enriched inulin and arabinoxylanoligosaccharides on colonic NH3-metabolism by means of lactose-[15N, 15N ']-ureide in healthy volunteers (2007) (1)
Mo1322 Serological and Genetic Markers As Predictors of Complicated Disease in Patients With Crohn's Disease (2013) (1)
Rectal bleeding accurately reflects mucosal inflammation in patients with Ulcerative Colitis (2015) (1)
Confirmation of the importance of anti-Saccharomyces cerevisiae antibodies (ASCA) in Crohn's disease (1998) (1)
254 A Multicenter Study to Evaluate Magnetic Resonance Enterography (MRE) for Selection of Crohn's Disease Patients for Inclusion Into a Therapeutic Clinical Trial (2014) (1)
Poster PresentationsP001 INFLIXIMAB THERAPY FOR REFRACTORY CROHN'S DISEASE (CD) DECREASES THE LONG-TERM NEED FOR BOWEL SURGERY (2008) (1)
Improvement in health related quality of life in infliximab-treated moderate-tosevere active ulcerative colitis patients: Improvement overall and by baseline disease activity: O-0019. (2007) (1)
Cyclosporine therapy for ulcerative colitis does not cause permanent renal damage (1999) (1)
Study on CARD15 and TLR4 polymorphisms in children with early diagnosed IBD and their family members (2005) (1)
The production of milk and egg proteins, enriched with stable isotopes, for the in vivo study of protein assimilation and metabolism during feeding: an European collaborative study (1998) (1)
Steroid Sparing Results in Further Improvement in Quality of Life in UC Patients in Remission: 1042 (2006) (1)
Serology panel for prediction relapse after discontinuation of infliximab in patients with Crohn's disease achieving clinical remission (2015) (1)
Efficacy of Certolizumab Pegol in Crohnʼs Disease Patients with Secondary Failure to Infliximab Is Not Affected by Concomitant Medications: 1216 (2009) (1)
OP19 Genetic and functional evidence for a role for CYLD in Crohn's disease: Results from a European consortium (2012) (1)
Natalizumab is effective without the concomitant use of immunosuppressants or corticosteroids for the induction and maintenance of response and remission in patients with Crohnʼs disease: P-069. (2008) (1)
Granulomas, pattern recognition receptors (PRR) and phenotypes of Crohn's disease (CD) (2004) (1)
P024 Repeated cycles of DSS inducing a chronically relapsing inflammation: A novel model to study fibrosis using in vivo MRI T2 relaxometry (2012) (1)
Poster PresentationsP016 FLEXIBILITY IN INTERVAL AND DOSING OF INFLIXIMAB ENABLES MAINTAINED RESPONSE OF PATIENTS WITH CROHN'S DISEASE (2008) (1)
T1814 Subclinical Intestinal Dysbiosis in Unaffected First-Degree Relatives of Crohn's Disease Patients (2010) (1)
Poster PresentationsP011 GLOBAL SAFETY OF ADALIMUMAB IN CROHN'S DISEASE CLINICAL TRIALS (2008) (1)
Natalizumab Improves the Health Related Quality of Life (HRQOL) in Crohnʼs Disease Patients: 842 (2005) (1)
The Mucosal Gene Expression of Enzymes Involved in Butyrate Uptake and Oxidation is Down Regulated in Ulcerative Colitis (2011) (1)
Natalizumab Induces Sustained Response and Remission in the Absence of Concomitant Immunosuppressants in Patients with Crohnʼs Disease Who Failed Prior Anti-TNFα Therapy: 1022 (2007) (1)
Su1219 Serum Neutrophil Gelatinase B-Associated Lipocalin and Matrix Metalloproteinase-9 (NGAL-MMP-9) Complex As a Surrogate Marker for Mucosal Healing in Patients With Crohn's Disease (2015) (1)
Prediction of response to infliximab in luminal and fistulizing Crohn's disease based on a decision making model using an apoptotic pharmacogenetic index and clinical predictors (2005) (1)
Corrigendum: Responsiveness of Endoscopic Indices of Disease Activity for Crohn’s Disease (2017) (1)
Altered Colonic Metabolite Profile in Active Versus Quiescent Ulcerative Colitis (2011) (1)
P205 - Outcome of patients with Crohn's disease and primary sclerosing cholangitis in CHARM and GAIN (2009) (1)
The combined 13c-glycine/14c-octanoic acid breath test to monitor gastric-emptying rate of liquids and solids simultaneously (1994) (1)
Endogenous and exogenous protein, escaping digestion and absorption in the small intestine after ingestion of a physiological load of egg protein (1997) (1)
Early Responses in Patient-reported Outcomes Are Predictors for Mucosal Healing in Patients with Moderately to Severely Active Ulcerative Colitis Treated with Golimumab: Results from PURSUIT SC Induction: 1723 (2013) (1)
P159 Predictors of complicated disease in Crohn's disease and ulcerative colitis (2012) (1)
Multi Drug Resistance Gene Single Nucleotide Polymorphisms in Inflammatory Bowel Disease (2006) (1)
Long-Term Follow Up of Endoluminal Anti-Reflux Procedures for GERD: Single-Center Experience with 3 Procedures (2005) (1)
P459 Predominant dysbiosis in patients with ulcerative colitis is different from Crohn's disease patients (2012) (1)
Efficacy of Pre-Treatment Biopsies in Predicting Final Histopathology of Endoscopically Resected Early Malignancies in the Upper Gastrointestinal Tract (2009) (1)
Adalimumab pharmacokinetics and concentration-effect relationship in Crohn's disease (2012) (1)
Phenotypical and functional characterization of the antigen presenting cell in Crohn's disease (2000) (1)
Su1280 The Modified Mayo Endoscopic Score (MMES): A New Score for the Assessment of Extension and Severity of Endoscopic Activity in Ulcerative Colitis (UC) Patients (2014) (1)
W1108 Remission, Response, and Quality-of-Life Improvement in Patients with Crohn's Disease Treated with Adalimumab in the Access Trial (2009) (1)
Squamous papilloma of the oesophagus and human papilloma virus (1994) (1)
Sa1202 Relationships Between Clinical Remission, C-Reactive Protein Normalization and Mucosal Healing in Crohn's Disease: Analyses From the SONIC trial (2013) (1)
Tolerability of Shortened Infliximab Infusion in Scheduled Maintenance Therapy for IBD: A Prospective Multi-center European Cohort Study (2013) (1)
Effect of disease duration on ‘deep remission’ (2011) (1)
Transendothelial migration of inflammatory cells is promoted in early postoperative Crohn's recurrence (1996) (1)
Su1292 Biomarker Panel for Prediction of Mucosal Healing in Patients With Crohn's Disease Under Infliximab Therapy (2014) (1)
Efficacy of certolizumab pegol in Crohnʼs disease patients with secondary failure to infliximab is not affected by concommittant medications: P-0035. (2009) (1)
The role of laser therapy in the palliative treatment of esophageal cancer. (1991) (1)
Sa1266 Interferon-γ Release Assay Versus Tuberculin Skin Test in Patients With Moderate-to-Severely Active Ulcerative Colitis: Results From the PURSUIT UC Program (2015) (1)
Crohn disease is associated with the Toll-like receptor (TLR)-4 polymorphism Asp299Gly: further evidence for a deficient bacterial recognition in the triggering of the disease (2003) (1)
Efficacy of Certolizumab Pegol is Not Affected by Baseline Anti-infliximab Antibody Status in Patients with Crohnʼs Disease with Secondary Infliximab Failure: 1217 (2009) (1)
Transmission of CARD15 (NOD2) variants in families with Crohns disease (2003) (1)
Sa1777 - Combined Clinical and Biological Response (Concomitant Crp and Fecal Calprotectin Reductions) in Induction and Maintenance from the Phase 3 Ustekinumab Crohn's Disease Studies (2018) (1)
Anti-murine TNF-alpha induces apoptosis of peritoneal macrophages from SCID mice (2003) (1)
EFFICACY ASSESSMENT OF NATALIZUMAB IN PATIENTS WITH CROHNʼS DISEASE AND PRIOR HISTORY OF INFLIXIMAB THERAPY: 831 (2004) (1)
Long-Term Safety of Certolizumab Pegol in Crohnʼs Disease: Integrated Safety Findings on Serious Adverse Events of Special Interest (2008) (1)
European Experience with ND: YAG and Argon Laser for Therapy of Upper Gastrointestinal Bleeding (1983) (1)
Characterization of Mucosal Healing With Adalimumab Treatment in Patients With Moderately to Severely Active Crohn’s Disease From EXTEND: 1611 (2014) (1)
Effect of infliximab treatment on colonic mucosal gene expression profiles in patients with inflammatory bowel disease (2008) (1)
Staging of rectal tumors by means of endoscopic ultrasound (1996) (1)
Maintenance Therapy With Certolizumab Pegol After Induction Therapy for Active Crohn's Disease: 6-Month Results (2011) (1)
S1201 Genetic Variants in Autophagy Related Genes and Granuloma Formation in Patients with Crohn's Disease (2009) (1)
Gastric-emptying of a mixed liquid-oil meal in healthy-volunteers, as measured by breath tests (1994) (1)
Genetics of Inflammatory Bowel Disease: How Modern Genomics Informs Basic, Clinical and Translational Science (2010) (1)
A new type of self-expanding metallic stent for palliation of obstructing rectal adenocarcinoma (1995) (1)
Infliximab Reduces UC-Related Hospitalizations Requiring High-Dose Corticosteroids: 1052 (2006) (1)
Gene expression profiling to predict the response of infliximab in patients with UC (2007) (1)
DOP033 Evaluation of site versus central assessment of endoscopies in Crohn's disease: Comparison using data from EXTEND (2014) (1)
Lactulose causes an important and unpredictable acceleration of the orocaecal transit time (1997) (1)
Short and long term effects of resistant starch with or without wheat bran by means of lactose-[15N, 15N]-ureide to determine the site of fermentation in the colon (2005) (1)
IBDQ score is a sensitive instrument to assess short-term changes in disease related quality of life in patients with luminal Crohn's disease (2005) (1)
Deconvolution of octanoic acid breath test results to produce gastric emptying curves, correlating well with scintigraphy (1999) (1)
P119 Higher levels of infliximab may alleviate the need of azathioprine comedication in the treatment of patients with Crohn's disease: a SONIC post hoc analysis. (2017) (1)
S0645 Efficacy and Safety of Ustekinumab for Crohn's Disease Through 5 Years: Final Results From the IM-UNITI Long-Term Extension (2020) (1)
Stratification Crohn's disease patients according to their ASCA (anti-saccharomyces cerevisiae antibodies) expression (2002) (1)
Mo1790 Safety, Efficacy, and Pharmacokinetics of Golimumab in Patients with Moderately to Severely Active Ulcerative Colitis: PURSUIT-SC Long term Extension (2016) (1)
S1056 Quality-of-Life Improvements in Patients with Crohn's Disease Treated for 3 Years with Adalimumab in An Open-Label Extension of CHARM (2009) (1)
Sa1237 Prediction of Primary Response to Infliximab in Crohn's Disease: A Matrix-Based Prediction Model (2014) (1)
Infliximab Therapy for Pediatric Crohn Disease and Ulcerative Colitis (2013) (1)
Exhaled nitric oxide correlates with the activity index of Crohn's disease (CD) and colitis ulcerosa (CU) (1999) (1)
Digestibility of raw and cooked egg protein is accurately evaluated by breath test technique (1997) (1)
Budesonide in collagenous colitis: A prospective double blind controlled trial with histologic follow-up (2000) (1)
Infliximab Induces Regulatory Macrophages in Responders but Not in Non-Responders (2011) (1)
P150 - Tolerability and safety of accelerated infliximab infusions: a prospective referral center registry and patient survey (2009) (1)
Kinetics of ASCA: A time-related study in a Belgian CD population (2000) (1)
Faecal bacterial DGGE profiles of Crohn's disease patients are different from those of their healthy first degree relatives and matched healthy controls (2007) (1)
Surgery is associated with fluctuations in ASCA levels suggesting antigenic stimulation (2000) (1)
P661 Endoscopy-based therapeutic management in postoperative recurrent Crohn’s disease: Results of a multi-centre retrospective study (2018) (1)
Improvement in Patient Quality of Life during Treatment with Infliximab, Azathioprine, or Combination Infliximab+Azathioprine for Moderate-to-severe Ulcerative Colitis: 1806 (2013) (1)
Infliximab Therapy Improves Health Related Quality of Life in Ulcerative Colitis Patients: 792 (2005) (1)
Anti-interleukin 12 antibody prevents experimental colitis in SCM mice reconstituted with CD45RBhigh CD4+ T cells (2000) (1)
Toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with ulcerative colitis (UC)0 (2003) (1)
Corrigendum: Difference in Pathomechanism Between Crohn’s Disease and Ulcerative Colitis Revealed by Colon Transcriptome (2019) (1)
Microscopic spectrum of duodenitis in Crohn's disease (1993) (1)
Maintenance of remission in Crohn’s disease (2000) (1)
W1196 Stability of Gut Microbiota Over Time in Crohn's Disease Patients Compared to Healthy Relatives (2008) (1)
Small intestinal transit is slowed in a subset of patients with chronic constipation: Studies using carbon labeled breath tests (2000) (1)
Do Antibiotics have a Role in Crohn's Disease? (2008) (1)
Coloscopie, klinische toepassingen (1976) (1)
Adalimumab Maintains Clinical Remission and Response in Patients with Active Crohnʼs Disease: Results of the CHARM Trial (2006) (1)
Natalizumab induces and maintains continuous response and remission in patients with active Crohnʼs disease despite prior anti-tumor necrosis factor-alpha treatment: O-033. (2008) (1)
Remission and Clinical Response Induced and Maintained in Patients with Active Crohnʼs Disease Treated for 1-Year Open-Label with Adalimumab: 858 (2005) (1)
Influence of high dose omeprazole on gastric emptying rate of solids and rate of intraduodenal lipolysis in normal subjects (1996) (1)
P566 A matrix-based prediction model for primary response to infliximab in Crohn's disease patients (2014) (1)
The increase of intestinal permeability caused by oral indomethacin is reduced by smoking (1997) (1)
Sustained Mucosal Healing in Adalimumab-Treated patients with moderate to severe Ileocolonic Crohnʼs Disease: Results of the EXTEND Trial: P-0028. (2009) (1)
P187 MRI T2 relaxometry to image fibrosis in patients with Crohn's disease (2014) (1)
Diagnostic value of a serologic panel of markers in inflammatory bowel disease (IBD) (2002) (1)
P095 Long-Term Safety of Azathioprine Treatment in Inflammatory Bowel Disease: Results From a Single Referral Center (2007) (1)
Treatment of tracheo-esophageal and bronchoesophageal fistulas with a polyurethane-covered self-expanding metallic stent (1995) (1)
O04 Multidrug Resistance (MDR) Gene Polymorphisms Influence Outcome of Azathioprine and Glucocorticoids in Patients With Inflammatory Bowel Disease (2007) (1)
P281 Combined clinical and biological response (concomitant CRP and faecal calprotectin reductions) in induction and maintenance from the phase 3 ustekinumab Crohn’s disease studies (2018) (1)
article : infliximab for Crohn ’ s disease treatment – shifting therapeutic strategies after 10 years of clinical experience (2011) (1)
Rapid Response to Human Anti-TNF Monoclonal Antibody Adalimumab in Patients with Moderate to Severely Active Crohnʼs Disease in the CLASSIC Study: 850 (2005) (1)
In vitro evaluation of IL-18 effects in Crohn's disease (2001) (0)
NEW LASER TECHNIQUES IN UPPER GASTRO-INTESTINAL BLEEDING (1988) (0)
DOP030 Feasibility, precision and reproducibility of MR enterography for detection of inflammation in Crohn's Disease in a multicenter clinical trial (2014) (0)
Low prevalence of NOD2/CARD15 and TLR4 gene polymorphisms, ASCA and pANCA in inflammatory bowel disease patients from northwest Greece participating in the EC-IBD Study Group cohort (2009) (0)
Biphasic impairment of the mucosal barrier function in rat small bowel in vitro by TNF (2003) (0)
Balloon dilatation of ileo-colonic anastomosis in Crohn’s disease (2012) (0)
Natalizumab Induction Therapy Results in Improved Quality of Life in Patients with Crohnʼs Disease: 1149 (2006) (0)
Current Limitations, New Technological Directions and Areas of Investigation — Panel Discussion (1983) (0)
Molecular Profiling of Early Crohn's Disease Using the Post-Operative Recurrence Model (2017) (0)
Distinct gene expression profiles are associated with induction of fibrosis and with additional recovery in chronic DSS colitis (2013) (0)
Correlation Between Endoscopic and Histological Activity in Adults with Moderate to Severe Crohnʼs Disease: Data from EXTEND: 2016 ACG Presidential Poster Award: 739 (2016) (0)
CD4+ T cells mediate epithelial colonic barrier and secretory function in SCID mice (2003) (0)
Tu1965 Restoration of FOXP3 Regulatory T Cells Correlates With Clinical Response to Anti-TNF Therapy for IBD (2012) (0)
Amino acid absorption in the colon is evidenced by means of a colonic instillation study using 13C-leucine (2006) (0)
Prevalence of helicobacter-pylori infection in school-children in countries with high and low socioeconomic-status and different trends in incidence of gastric-cancer (1995) (0)
Effect of short- and long-term dieatry intake of oligofructose-enriched inulin on the colonic fate of NH3 in healthy volunteers (2006) (0)
W1130 Infliximab Does Not Increase Short-Term Post-Operative Infectious Complications in Patients with Ulcerative Colitis (2008) (0)
Anti-murine TNF-A reverses Tnbs colitis in mice but not oxazolone colitis: Potential role of apoptosis induction (2005) (0)
Is Keeping the Colon the Ultimate Marker of Success in Ulcerative Colitis (2009) (0)
Crohn’s disease susceptibility genes involved in microbial sensing, autophagy and endoplasmic reticulum (er) stress and their interaction (2013) (0)
P381 Adalimumab efficacy and safety by disease duration: analysis of pooled studies of Crohn's disease. (2017) (0)
High age adjusted risk for daughters of patients with Crohn's disease (1996) (0)
Effect of switching to budesonide on the quality of life of patients with steroid-dependent Crohn's disease (2001) (0)
Endoscopic features in gastroduodenal Crohn's disease (1979) (0)
Persistent dysregulated colonic mucosal gene expression in ulcerative colitis patients with endoscopic healing after infliximab or vedolizumab therapy (2015) (0)
Infliximab targets mucosal inflammatory cells, resulting in histological and endoscopic healing in patients with Crohn's disease (2003) (0)
Immunomodulatory role of IL-4 on regulatory T cells in vitro and in experimentel colitis (2004) (0)
Strictures in inflammatory bowel disease: are there differential indications for surgery or endoscopic dilatation? (2003) (0)
Clinical and biological efficacy to anti-TNF therapy relates to reciprocally modulating blood and intestinal mucosa Foxp3 expression (2010) (0)
S1236 Rapid Normalisation of C-Reactive Protein (CRP) and Scheduled Therapy Are Associated with Sustained Clinical Benefit to Infliximab Long-Term (2008) (0)
Use of serology and genetics to differentiate inflammatory bowel disease phenotypes (2007) (0)
Pneumatic dilation for severe post-Nissen dysphagia: A prospective follow-up study (2001) (0)
Blockade of CD40 signaling prevents experimental colitis in SCID mice reconstituted with CD45RBhigh CD4+ T cells (1999) (0)
Differential effect of inulin and lactulose on the colonic NH3-metabolism evaluated using a stable isotope biomarker (2005) (0)
Proctitis: A particular type of Crohn's recurrence following ileal resection (1998) (0)
Adalimumab is Effective for Inducing Clinical Remission at Week 4 Regardless of Baseline Corticosteroid Use: Pooled Analysis of Four Clinical Trials: 1181 (2010) (0)
W1206 Impaired Sulphide Detoxification in Ulcerative Colitis Is Related to Inflammation (2008) (0)
Effect of short- and long-term administration of Lactobacillus casei Shirota, oligofructose-enriched inulin and their synbiotic combination on the colonic fate of ammonia (2006) (0)
20 Mucosal miRNA and Gene Expression As Biomarker of Response to Infliximab in Ulcerative Colitis (2014) (0)
IL-13 delays recovery after dextran sodium sulfate induced acute colitis (2011) (0)
CARD15, TLR4, ASCA AND PANCA IN PAEDIATRIC IBD: A FAMILY STUDY: PG2-04 (2005) (0)
Infliximab induces apoptosis of human monocytes in vitro and in THP-1-SCID-mice model (2002) (0)
Laser capture microdissection is compatible with 16S rDNA-based genomic technologies in bowel biopsies from Crohn??s disease patients (2005) (0)
Gastric-emptying in patients with duodenal-ulcer (du) and helicobacter-pylori (hp) infection (1994) (0)
Repeated cycles of DSS inducing a chronically relapsing inflammation: a novel model to study fibrosis (2012) (0)
Baseline levels of p-cresol, 15N-excretion and bifidobacteria influence the response of prebiotic treatment in healthy subjects (2007) (0)
Interobserver Variability of Methylene Blue Guided Chromoendoscopy in Patients with Suspicion of Dysplastic Barrett’s Oesophagus (2008) (0)
5-ASA and acetyl-5-ASA in plasma, urine and faeces from patients with inflammatory bowel disease during 3 g daily (T.I.D. 1 g) dosing off a slow release 5-ASA formulation (1990) (0)
Anal carcinoma in Crohn's disease: Late diagnosis, a potential risk factor in poor outcome (1997) (0)
Expression of interleukin-15 in inflammatory bowel disease (1998) (0)
NOD2/CARD15 and TLR4 gene polymorphisms and histopathological features of surgical specimens in Crohn's disease (2004) (0)
P033 Prevention of recurrent Clostridium difficile infection by neutralizing monoclonal antibodies in a hamster relapse model (2014) (0)
A stop codon mutation in the TUCAN (CARD8,cardinal) gene is associated with less favorable outcome to infliximab treatment in Crohns disease (CD) (2005) (0)
Reanalysis of death risk in long-term follow-up in infliximab patients versus controls (2010) (0)
No induction of cytokine release by hsp-65 in biopsy cultures from crohns-disease patients (1995) (0)
INFLAMMATORY BOWEL DISEASE. A CASE PRESENTATION FROM AMSTERDAM WITH A PANEL DISCUSSION IN BARCELONA (1998) (0)
Role of PAI-1 and TAFI in the elevated thromboembolic risk seen in IBD patients (2010) (0)
Crohn's-like pattern in colonic mucosal biopsies in mycophenolate-mofetil treated patients: A link to side effects? (2002) (0)
The relationship between the presence of ASCA antibodies and increased intestinal permeability in Crohn's disease (1999) (0)
Effect of simultaneous and long-term administration of Lactobacillus casei Shirota and Bifidobacterium breve on the colonic fate of NH3 (2005) (0)
Drug prophylaxis of recurrence of Crohn's disease after resection: the way to go. (1998) (0)
Safety of switching systemic steroids to budesonide modified-release capsules in steroid-dependent patients with inactive Crohn's disease (2001) (0)
A new breath test for fat maldigestion (1978) (0)
Sa1280 Prevention of Recurrent Clostridium difficile Infection by Neutralizing Monoclonal Antibodies in a Hamster Relapse Model (2014) (0)
Agonistic Anti-4-1bb (cd 137) monoclonal antibody (mab) aggravates experimental colitis, but do not abrogate tolerance in the T cell transfer model of colitis (2005) (0)
Protein assimilation in normal subjects and patients with pancreatic disease, studied with a C-13 egg white breath test (1998) (0)
P087 Differentially expressed microRNAs regulate expression of genes with clinical interest in inflamed colon of patients with ulcerative colitis (2013) (0)
14 Maintenance of remission in Crohn's disease (2000) (0)
Cytoplasmic accumulation of p53 occurs in intestinal metaplasia associated with gastric ulcers but not with duodenal ulcers (1998) (0)
Prospective evaluation of endoscopic ultrasound (EUS) guided fine needle aspiration (FNA) for pancreatic lesions (2001) (0)
PR3-ANCA: A promising biomarker for the differentiation of ulcerative colitis and Crohn’s disease (2013) (0)
Ferrante M, D'Hoore A, Vermeire S, et al.. Corticosteroids but not infliximab increase short-term postoperative infectious complications in patients with ulcerative colitis (2009) (0)
Colonic fate of malabsorbed egg protein (1998) (0)
S1205 Stability of Granuloma Formation Over Time in Patients with Crohn's Disease and the Relationship with Variants in Autophagy Genes (2009) (0)
Increased HSP-65 antibodies but decreased lymphocyte proliferative response to HSP-65 in Crohn's disease (1994) (0)
Adalimumab maintains long-term remission through 2 years in patients with moderate to severe Crohnʼs Disease: P-0085. (2008) (0)
Low ileal IL-10 mRNA levels predict endoscopic recurrence in patients operated on for Crohn's disease (CD) (2000) (0)
Safety of adalimumab in global clinical trials of patients with Crohn's disease. (2011) (0)
Infusion of ileal fluid through diverted neoterminal ileum causes acute mucosal lesions in patients operated for Cronh's ileocolitis (1994) (0)
Recurrence of Crohn's disease after ileal resection: is prophylaxis useful (1996) (0)
Mo1158 MRI T2 Relaxometry to Image Fibrosis in Patients With Crohn's Disease (2014) (0)
Reply to both letters (1993) (0)
Is ASCA (anti-saccharomyces cerevisiae antibodies) related to the major histocompatibility complex (HLA)? (2000) (0)
The Nf-kappa B regulator CARD8/Tucan/Cardinal is a Crohn's disease modifying gene and influeces response to microbial antigens (2006) (0)
Inflammatory lesions of the myenteric plexus in Crohn's disease (1999) (0)
Comment on 'Predicting the response to infliximab from trough serum levels' Response (2010) (0)
Therapeutic drug and immunogenicity monitoring of the monoclonal antibody infliximab to personalize treatment of inflammatory bowel disease patients (2012) (0)
CD40 ligand is overexpressed and induces cytokine production in inflammatory bowel disease (1999) (0)
PhD Thesis STUDY OF NITRIC OXIDE SYNTHASE ISOFORMS IN INFLAMMATRORY BOWEL DISEASE Dr . KÁROLY PALATKA UNIVERSITY OF DEBRECEN MEDICAL AND HEALTH SCIENCE CENTER DEBRECEN (2006) (0)
A separation model for breath test analysis (1995) (0)
Dealing With Infusion Reactions (2007) (0)
Hyperexpression of CD40 ligand and its role in pathogenic cytokine producton in inflammatory bowel disease (1999) (0)
Breath tests after cecal instillation of lactose-[13C]ureide show immediate yet diverse colonic bacterial metabolism (2000) (0)
cA2 can upregulate TCR/CD3 complex-mediated CD28-triggered IFN-gamma production in pathological ileal Crohn's disease (1999) (0)
Clinical and immunological effects of ornidazole in active crohns-disease - an 8-week open-label trial (1995) (0)
Compassionate Use of Certolizumab Pegol in Patients with Crohnʼs Disease Who Have Failed Previous TNF Inhibitor Therapies: 1149 (2010) (0)
Predictive Value of C-Reactive Protein Level Changes On the Long Term Outcome of Infliximab in Crohn's Disease (2009) (0)
[Cholestereic and steatogenic diarrhea in ileal dysfunction]. (1977) (0)
Light microscopic, immunohistochemical and ultrastructural immunocytochemical follow-up study of Whipple's disease (1987) (0)
Amino acid fermentation in the colon is impaired upon simultaneous administration of fermentable carbohydrates: results of a direct instillation study using 13C-leucine (2006) (0)
Additional evidence for an inflammatory bowel disease (IBD) locus on 14q11–12 (2000) (0)
Effect of short- and long-term administration of Lactobacillus casei Shirota and Bifidobacterium breve on the colonic fate of protein fermentation metabolites phenol and p-cresol (2006) (0)
Stents versus endoscopic laser therapy (ELT) in malignant dysphagia: A comparision of complication rates (1997) (0)
Mo1735 Fibrogenesis Is Innate Immunity Driven in Chronic DSS Colitis and Associated With Distinct Gene Expression Patterns (2014) (0)
Case presentation: Refractory Crohn's disease (2000) (0)
nfluence of Trough Serum Levels and Immunogenicity on Long-term utcome of Adalimumab Therapy in Crohn ’ s Disease (2013) (0)
Endoscopic Treatment of Early Esophageal Cancer: Safety and Efficacy in An Early Training Stage (2009) (0)
W1222 Intestinal Mucosal Expression of Matrix Metalloproteinase and ADAM Genes in Patients With Inflammatory Bowel Disease and the Impact of Infliximab Therapy (2010) (0)
Simultaneous measurement of gastric emptying and orocecal transit in children using 13C breath tests (1998) (0)
Interaction of Crohn's disease susceptibility genes in autophagy and endoplasmic reticulum (ER) stress pathways in a belgian cohort (2011) (0)
P465 Efficacy of ustekinumab for induction and maintenance of histological healing in patients with Crohn's disease. (2017) (0)
Republished: Recent advances: personalised use of current Crohn's disease therapeutic options (2014) (0)
Therapy of Upper Gastrointestinal Bleeding: Electrocautery vs. ND:YAG Laser — Panel Discussion (1983) (0)
Involvement of the stomach and duodenum by Crohn's disease (1980) (0)
Summary (1999) (0)
Dose dependent effect of administration of lactulose on the colonic NH3-metabolism (2005) (0)
600 - Endoscopy Based Therapeutic Management in Postoperative Recurrent Crohn's Disease: Results of a Multi-Center Retrospective Study (2018) (0)
Breath tests in H.pylori infection: methodological aspects (1997) (0)
Trace elements: selenium as an example (1999) (0)
Effect of oligofructose-enriched inulin and arabinoxylooligosaccharides on intestinal bacterial enzyme activities (2007) (0)
P062 Ileal gene expression profiling of Crohn's disease underlines the importance of the inflammatory load during the disease course (2013) (0)
5-ASA enemas twice weekly are as effective as oral 5-ASA 1 gram bid to maintain remission in left-sided ulcerative colitis (1996) (0)
Gastric unusual lymphoid infiltrates - as marginal zone cell lymphomas (MZCL) - may regress after Helicobacter pylory (Hp) eradication (2001) (0)
Pseudomelanosis of the esophagus (1989) (0)
Colonic mucosal expression of barrier genes in patients with inflammatory bowel disease before and after first infliximab treatmen (2009) (0)
Anti-TNF-alpha treatment for perianal fistulizing Crohn's disease (2001) (0)
Sa1770 Simultaneously Restoration of FOXP3 (+) Regulatory T Cells Subsets, Type 1-Like Regulatory T Cells and B Cells Correlates With Clinical Response to Infliximab Therapy for IBD (2013) (0)
CC chemokine receptor 5 (CCR-5) and serological markers ASCA and pANCA in inflammatory bowel disease (IBD) (2000) (0)
Mucosal expression of human heat shock proteins in Crohn's disease (1994) (0)
Case presentation: Crohn's disease with perianal involvement (2000) (0)
Cell-Dependent Cytokine Production Bowel Disease and Regulates Local T IL-15 Is Highly Expressed in Inflammatory (2013) (0)
P144 Serum neutrophil gelatinase B-associated lipocalin–matrix metalloproteinase-9 (NGAL-MMP-9) complex as a surrogate marker for mucosal healing in ulcerative colitis (2013) (0)
S1190 The Impact of Infliximab Therapy On Colonic Mucosal Expression of Barrier Genes in Patients with Inflammatory Bowel Disease (2009) (0)
Restoration Of B Cells Correlates With Clinical Response To Anti-Tnf Therapy (2012) (0)
M2044 Genetic Variations in GLI-1 and MDR-1 Do Not Predict Disease Progression in Patients with Ulcerative Colitis (2008) (0)
Expression of adhesion molecules in early recurrent Crohn's disease: is ileum different from colon (1997) (0)
Biochemical determination of loss of response precedes clinical loss of response (2010) (0)
W2000 Synbiotic Intervention Changes the Colonic Metabolite Fingerprint of Healthy Subjects (2009) (0)
Multicenter prospective validation of a simple endoscopic score for Crohn's disease (SES-CD) (2003) (0)
Case presentation: Mild to moderate Crohn's disease of the small and large bowel (2000) (0)
Radiological sacroiliitis in Crohn's disease: A multicenter association study (2006) (0)
Interleukin-12 abrogates the effector functions of regulatory T cells in an experimental colitis (2001) (0)
The severity of somatic complaints in Crohn's disease: the role of psychological factors (2003) (0)
Biologics in Crohn’s Disease and Ulcerative Colitis: Focus on Tumor Necrosis Factor Antagonists (2007) (0)
[Endoscopic sclerosis for hemorrhage caused by peptic ulcer: a real advance]. (1990) (0)
Effect of cA2 on pathological ileum of Crohn's disease: not merely TNF down regulation (1999) (0)
Tu1344 Serology Panel for Prediction of Relapse After Discontinuation of Infliximab in Patients With Crohn's Disease Achieving Clinical Remission (2015) (0)
S1173 Evidence for the Autophagy Gene ULK1 As Susceptibility Gene in Crohn's Disease (2009) (0)
Increased small-intestinal permeability - a feature associated with crohns-disease but not with ulcerative-colitis (1995) (0)
The impact of infliximab therapy on colonic mucosal expression of barrier genes in patients with inflammatory bowel disease. (2009) (0)
Mucosal gene signatures to predict response to infliximab in patients with inflammatory bowel disease (2008) (0)
W1264 Kinetics of C-Reactive Protein (CRP) Following Maintenance Infliximab Treatment in Crohn's Disease Identifies Profiles of Patients With Better Outcome (2010) (0)
W1237 Haptoglobin Poymorphisms are Associated With Ulcerative Colitis and Crohn's Disease (2010) (0)
Can we screen for the risk of PML; A case control cohort study in Crohn's disease patients treated with immunosuppressives (2007) (0)
No association between month of birth and Crohn's disease (2003) (0)
Influence of long-term intervention of lactulose and Saccharomyces boulardii cells on the colonic generation of p-cresol (2005) (0)
Infliximab for Ulcerative Colitis (2014) (0)
Su1277 Increased Expression of T Cell Associated Genes in Baseline Biopsies From TNF Antagonist Naive Patients That Achieve Remission With Etrolizumab Treatment in a Phase II Trial in Moderate to Severely Active Ulcerative Colitis (2014) (0)
Effect of Oligofructose Enriched Inulin (OF-IN) on Bacterial Composition and Disease Activity of Crohn's Disease Patients: Results From a Double-Blind Randomized Controlled Trial (2011) (0)
Abstracts of the Young Investigators Award of the Belgian Society of Internal Medicine, Congress 9 - 10 December 2005, Le Marais, Brussels (2005) (0)
Expression of barrier genes in the colonic mucosa of IBD patients (2009) (0)
Diagnostic and Therapeutic Approaches to Postoperative Recurrence in Crohn's Disease (2010) (0)
Chromoendoscopy with Methylene Blue Helps to Localize Dysplasia in Patients with Suspicion of Dysplastic Barrett's Esophagus (2007) (0)
The intraluminal digestion is a rate limiting step in the assimilation process of egg protein (1997) (0)
[Gastroduodenal hemorrhage: endoscopic treatment]. (1991) (0)
How localized is ulcerative proctitis (1987) (0)
Benefits of Adalimumab dosage adjustment for patients with Crohnʼs Disease: An analysis of the CHARM study: P-0063. (2008) (0)
Concordance in clinical characteristics of Crohn's disease: A within generation phenomenon (1996) (0)
Resistant starch influences the colonic ammonia metabolism but not the protein fermentation (2005) (0)
Role of CD137 (4-1BB) in the SCID T cell transfer colitis model (2003) (0)
P0653 EFFICACY AND SAFETY OF INFLIXIMAB IN CHILDREN WITH CROHN???S DISEASE: A SINGLE CENTER EXPERIENCE (2004) (0)
[Clinical application of the 14CO2 bile acid breath test in gastroenterology]. (1977) (0)
A Computerised System for Recording and Reporting on Upper Gastrointestinal Endoscopy Data (1988) (0)
Expression of gelatinase B in early recurrent Crohn's disease (1997) (0)
A General Overview of Teatment Techniques — Panel Discussion (1983) (0)
Efficacy of certolizumab pegol is not affected by baseline anti-infliximab antibody status in patients with Crohnʼs disease with secondary infliximab failure: P-0030. (2009) (0)
1 - Colonic mucosal expression of barrier genes in patients with inflammatory bowel disease before and after first infliximab treatment (2009) (0)
Endoscopic aspects of recurrences or relapses of ileal Crohn's disease. (1984) (0)
Single nucleotide polymorphisms of the MDR1 gene in inflammatory bowel disease (2006) (0)
Molecular landscape of early Crohn's disease using an integrated approach of mRNA/miRNA profiling and genomics (2016) (0)
The lactose-(13C)-ureide breath test in combination with the (14C)-octanoate breath test to assess pharmacological modulation by erythromycin and propantheline of proximal gastro-intestinal transit (1998) (0)
P218 - Stability of granuloma formation over time in patients with Crohn's disease and the relationship with variants in autophagy genes (2009) (0)
822 Mucosal Gene Signatures to Predict Response to Infliximab in Patients with Inflammatory Bowel Disease (2008) (0)
Adalimumab is effective for inducing clinical remission at week 4 regardless of baseline corticosteroid use (2011) (0)
Simultaneous measurement of gastric-emptying rate of solids and rate of intraduodenal lipolysis by means of a dual-labeled breath test (1993) (0)
P046 Differential expression of microRNAs in inflamed colonic mucosa of patients with ulcerative colitis (2012) (0)
Guide for medical internship: Clinical training in the third medical year (1996) (0)
Biologicals: old and new ones (2006) (0)
Differential effect of long term dietary intake of lactulose and oligofructose-enriched inulin on the NH3-metabolism and predominant microbiota in the colon of healthy volunteers (2006) (0)
OC.03.6 GENETIC AND CLINICAL CHARACTERIZATION OF 43 MULTIPLE-AFFECTED INFLAMMATORY BOWEL DISEASE FAMILIES (2014) (0)
The prevalence of lymphoid follicles and aggregates in the gastric mucosa from neonatal period to young adulthood (1996) (0)
Efficacy and Safety of Certolizumab Pegol in patients with active Crohnʼs Disease who previously lost response or were intolerant to Infliximab: Open-Label induction results of the WELCOME Study: P-0066. (2008) (0)
Su1221 Symptom Scores Do Not Accurately Reflect Level of Mucosal Inflammation in Patients With Crohn's Disease (2015) (0)
Predictive value of patient-reported outcomes to mucosal healing in patients with moderately to severely active ulcerative colitis (2014) (0)
Preliminary evidence that development of early Crohn's recurrence in the neoterminal ileium is fecal stream dependent (1989) (0)
Mixed IBD families : a distinct entity within IBD (2007) (0)
Azathioprine induces mucosal healing in severe recurrent Crohn's ileitis after surgery (1995) (0)
Evaluation of short- and long-term effects of inulin on colonic urea-nitrogen-metabolism using 15N-lactose-ureide (2003) (0)
Specific forms of acute infectious colitis (1980) (0)
Egg protein digestion in normal subjects studied with a (CO2)-C-13 breath test (1996) (0)
Compassionate Use of Certolizumab Pegol in Patients with Crohnʼs Disease for Whom Treatment with One or Two Anti-TNFs Failed: 997 (2007) (0)
Efficacy and Safety of Ustekinumab for Crohnʼs Disease: Results From IM-UNITI Long-Term Extension Through 3 Years: Presidential Poster Award (2018) (0)
Card15 mutations and granulomas in CD (2003) (0)
Immunogenicity of infliximab in Crohn's disease - Reply (2003) (0)
The predictive value of enteroscopy for long term outcome in obscure GI bleeding (1995) (0)
Anti-α-enolase antibodies in inflammatory bowel disease (2007) (0)
The diagnostic problem of gasric unusual lymphoid infiltrates is not solved by the scoring scale of Wotherspoon (1999) (0)
Are protein fermentation metabolites involved in the pahogenesis of ulcerative colitis (1998) (0)
Tu1932 Differential Expression of MicroRNAs in Ileal Mucosa of Patients With Early, Recurrent and Late Crohn's Disease (2014) (0)
Dual immune suppressive activity of 4AZA1378 alleviates TNBS-induced colitis in mice (2005) (0)
P117 - Global safety of adalimumab in trials of patients with Crohn's disease (2009) (0)
Active Foxp3 (+) Regulatory T Cells Rather Than Other Foxp3 (+) T Cells Subsets CorrelateWith Clinical Response To Infliximab Therapy For IBD (2012) (0)
Pouchitis, similar to ulcerative colitis, is associated with decreased butyrate oxidation by the mucosa (2000) (0)
Tissue localisation of alpha-1-antitrypsin in the normal small intestine and in Crohn's disease (1981) (0)
T1796 Impaired Thiosulfate Sulfurtransferase (Tst) Enzyme Activity and Mucosal Gene Expression in Ulcerative Colitis (2010) (0)
124a ER Stress and Autophagy-Related Susceptibility Loci Translate Into a Measurable Functional Response in Crohn's Patients: A Potential Tool for Personalized Medicine (2014) (0)
Comparative performances of machine learning methods for classifying Crohn Disease patients using genome-wide genotyping data (2019) (0)
P147 Serological and genetic markers as predictors of complicated disease in patients with Crohn's disease (2013) (0)
Influence of lactulose on the pattern of fermentation metabolites in faecal samples in healthy volunteers (2007) (0)
Comparative performances of machine learning methods for classifying Crohn Disease patients using genome-wide genotyping data (2019) (0)
Research into treatment and aetiopathogenesis of chronic idiopathic inflammatory bowel diseases: Crohn's disease, ulcerative colitis and microscopic colitis (2002) (0)
Left-sided colitis : how localized is it ? (1987) (0)
A panel of serologic markers in twins with inflammatory bowel disease (2005) (0)
Functional IL12B Variant Interacts With Response to Infliximab Treatment in Crohn’s Disease (2005) (0)
In vivo T2 relaxometry to assess inflamamtion and fibrosis in a murine model of inflammatory bowel diseases (2011) (0)
Sa1241 Pharmacology of Etrolizumab in a Phase 2 Study in Moderate-to-Severely Active Ulcerative Colitis (2014) (0)
CD4 T cells regulate epithelial and subepithelial colonic barrier function in SCID mice (2003) (0)
Outcome of pregnancy in women with inflammatory bowel disease treated with anti-TNF therapy (2010) (0)
Undecided Issues About the Use of Lasers in Gastrointestinal Disease — Panel Discussion (1983) (0)
Injection Sclerotherapy for Peptic Ulcer Bleeding (1992) (0)
Laser photocoagulation of bleeding gastroduodenal ulcers: A morphological study (2005) (0)
Endometriosis and Crohn's disease (1997) (0)
P094 Clinical, Surgical and Genetic Risk Factors for Development of Pouchitis Following IPAA For Ulcerative Colitis (2007) (0)
Reply to Dr. Caprilli et al.'s letter. (2009) (0)
HPMPC treatment of a patient with esophageal and hypopharyngeal papillomatosis (1994) (0)
Sequential T2 Relaxometry as a Non-Invasive Assessment of Transmural Inflammation in a Murine Model of Chronically Relapsing Colitis (2012) (0)
Genetic and clinical characterization of 56 multiple-affected IBD families (2015) (0)
Like low grade marginal zone B-cell lymphomas (MZCL), atypical lymphoid infiltrates in stomach may regress after Helicobacter Pylori eradication (2001) (0)
PGU8: ANALYSIS OF THE DIRECT COST GENERATED BY INFLIXIMAB TO NORMALIZE QUALITY OF LIFE IN PATIENTS WITH CROHN'S DISEASE (2000) (0)
Estudio de la asimilación de proteínas usando técnicas de isótopos estables (2016) (0)
W1221 The Impact of Infliximab Therapy on Intestinal Mucosal Gene Expression of Endothelial Cell Adhesion Molecules in Patients With Inflammatory Bowel Disease (2010) (0)
Immunogenicity of anti-TNF biopharmaceuticals in inflammatory bowel disease (2011) (0)
AODWE-006 Efficacy of ustekinumab for induction and maintenance of histological healing in patient’s with crohn’s disease (2017) (0)
Longitudinal T2 relaxometry to monitor repeated cycles of DSS inducing a chronically relapsing inflammation (2012) (0)
Idiopathic arterio-venous malformations of the colon (1979) (0)
How useful is sucralose as permeability marker for the human small intestine and colon (2000) (0)
Tu1926 Mucosal Gene Expression Profiles in Pouchitis and in Active Ileal Crohn's Disease are Very Similar (2012) (0)
Effects of long-term administration of lactulose and Saccharomyces boulardii cells on serum lipids in healthy volunteers (2005) (0)
S1643 A Critical Function of Haptoglobin in Modulating TH17 Responses in Experimental Colitis (2009) (0)
Sererity and determinants of fatigue in Crohn's disease (2003) (0)
EFFICACY, SAFETY, AND TOLERABILITY OF NATALIZUMAB IN MAINTAINING CLINICAL RESPONSE AND REMISSION IN CROHNʼS DISEASE (ENACT-2): 788 (2004) (0)
Thio-Purine Methyl Transferase Gene Single Nucleotide Polymorphisms in Inflammatory Bowel Disease (2006) (0)
Mucosal Recolonization after Ileocecal Resection Differs in Crohn's Disease Patients Developing Postoperative Recurrence (2017) (0)
Characterization of Ulcerative Colitis Patients in the Golimumab Pursuit-Maintenance Study: Post-HOC Analyses of Patients who Maintained and did not Maintain Clinical Response Through Week 54 (2017) (0)
The pattern of increased small-intestinal permeability abnormalities in families with crohns-disease - genetic or nongenetic (1995) (0)
Future directions in inflammatory bowel disease management ☆ ded from h (2014) (0)
Role of plasminogen activator inhibitor and thrombin activatable fibrinolysis inhibitor in the elevated thromboembolic risk seen in inflammatory bowel disease patients (2011) (0)
The angiogenic chemokine granulocyte chemoattractant protein-2 (GCP-2) is selectively expressed by endothelial cells in ulcer beds in chronic inflammatory bowel diseases (IBD) (2006) (0)
P055 Integrated miRNA and gene expression profiling in patients with ulcerative colitis before and after infliximab treatment (2014) (0)
Concordance of serologic and genetic markers in twins with inflammatory bowel disease (2004) (0)
Colitis Inflammation in Chronic Experimental Control Tolerance or Induction of Mucosal B7 Interactions with CD28 and CTLA-4 (2001) (0)
497 Efficacy of Infliximab in Refractory Pouchitis and CD-Related Complications of the Pouch: A Belgian Case Series (2008) (0)
Randomised opencontrolled trial ofcolloidal bismuth subcitrate tablets andcimetidine inthetreatment of duodenal ulcer (1980) (0)
Dose-response effect of arabinoxylanoligosacharides on the colonic NH3- metabolism using lactose-(N-15, N-15')-ureide in healthy volunteers (2006) (0)
Fecal Lactoferrin (fLac) and Calprotectin (fCal) as Surrogate Markers of Mucosal Healing: Post-hoc Analysis from the PURSUIT SC Induction Study: 1864 (2015) (0)
M2043 Microarray Study of Mucosal Antimicrobial Peptides in Patients with Inflammatory Bowel Disease Before and After First Infliximab Treatment (2008) (0)
Induction of tolerance by blockade of CD40L and B7-1: studies in the T cell transfer model of colitis (2005) (0)
Influence of octreotide on gastric-emptying rate of solids, as measured by the c-14 octanoic-acid breath test (1994) (0)
Health-Related Quality of Life in TNF-Antagonist-Naïve Patients with Crohnʼs Disease During Short- and Long-Term Adalimumab Treatment: 974 (2008) (0)
Screening for colorectal cancer. (1995) (0)
P242 - Prioritization of mucosal protease/protease inhibitor candidate genes in inflammatory bowel disease through a systematic review analysis approach (2009) (0)
Response and Remission Are Associated with Improved Quality of Life in Patients with Ulcerative Colitis: 791 (2005) (0)
96 The Wnt Co-Receptor LRP6 as a New Factor in Ileal Crohn's Disease (2012) (0)
OP013 Status of ER stress and autophagy in Crohn's disease: From genetics to functional read-outs (2014) (0)
Two and four mg/kg/day of IV cyclosporine are equally effective in severe attacks of ulcerative colitis (2000) (0)
Tu1667 Mucosal Gene Expression Profiling of Early, Recurrent and Late Ileal Crohn's Disease Emphasizes the Importance of the Severity of the Inflammatory Process During the Disease Course (2013) (0)
Relation between gastric emptying and small bowel transit in normal subjects studied with breath tests (2000) (0)
Su1759 Differentially Expressed MicroRNAs in Inflamed Colon of Patients With Ulcerative Colitis Regulate Expression of Genes With Clinical Interest (2013) (0)
W1219 Genome-Wide Association Study for Ulcerative Colitis Demonstrates Novel Associations at Chromosome 22 and 7 (2010) (0)
Gut barrier hyperresponsiveness to indomethacin is limited to the epithelium in colitis in SCID mice reconstituted with CD4CD45RBhigh T cells (2003) (0)
S37 Reciprocal modulation of Foxp3 expression by anti-TNF therapy in blood and intestinal mucosa relates to the clinical and biological efficacy (2010) (0)
Prospective follow up of early lesions after ileal resection for Crohn's disease (1986) (0)
M1117 Seroreactivity to Faecalibacterium Prausnitzii and the Presence of This Microorganism in Feces of Crohn's Disease Patients and Controls (2009) (0)
Mo1814 Extracellular Matrix Protein Expression in Chronic Relapsing Dextran Sodium Sulphate Colitis Reflects Transmural Remodeling in Human Crohn's Disease (2013) (0)
Longitudinal mouse colon T2 monitoring of chronically relapsing inflammation induced by repeated cycles of DSS (2012) (0)
Evolution of gastric lesions caused by endoscopic photocoagulation with the Neodymium-Yag Laser (1979) (0)
ASCA and pANCA in a new Belgian IBD dataset (2000) (0)
Differentiating role of B7-CD28/CTLA-4 interaction in the induction of mucosal inflammation and regulatory T cell functions in chronic experimental colitis (2001) (0)
Safety of Adalimumab in patients with Crohnʼs Disease: Analysis of global clinical trials: P-0049. (2008) (0)
Mo1214 Long-Term Safety and Efficacy of Golimumab in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the PURSUIT-SC Maintenance Study Extension (2014) (0)
Increasing TNF-alpha and decreasing IFN-gamma tissue concentrations in early recurrent Crohn's disease and correlation with endoscopic lesions (1996) (0)
Acute colitis due to campylobacter infect (1980) (0)
High Levels of Thrombin Activatable Fibrinolysis Inhibitor and Plasminogen Activator Inhibitor Are a Risk Factor for Thromboembolism: A Case-Control Study in IBD Patients (2011) (0)
Epigenetic control of colonic inflammation via the methyl-binding protein Mbd 2 (2014) (0)
Anthracosilicosis of the esophagus (1985) (0)
Optimizing Patient Outcomes in the Treatment of Ulcerative Colit is (2013) (0)
The C-13-urea breath test (UBT) correlates with the bacterial load ansi the severity of inflammation in H-pylori (HP) gastritis (1997) (0)
Assessment of Fecal Markers and Clinical Outcomes in Patients With Moderately to Severely Active Ulcerative Colitis: Results from PURSUIT-SC Induction: 1700 (2014) (0)
Long-Term Safety of Adalimumab in Clinical Trials in Adult Patients With Crohnʼs Disease or Ulcerative Colitis: 1858 (2015) (0)
Short-term influence of lactulose and Saccharomyces boulardii cells on the protein fermentation metabolite p-cresol (2005) (0)
Treatment and follow-up of perforated gastric ulcers (1995) (0)
State-of-the-Art Lecture: The changing face of inflammatory bowel disease over recent decades (2008) (0)
T 2 relaxometry to image fibrosis in patients with Crohn ’ s disease (2014) (0)
Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment sustained infliximab treatment for Crohn's disease (2005) (0)
Long term stability of gut microbiota in Crohn’s disease patients compared to healthy relatives (2008) (0)
DNA-aneuploidy in colorectal carcinoma in Crohn's disease. (2000) (0)
Disease profile, selection criteria and outcome of patients referred to intestinal transplantation: a center experience (2005) (0)
W1629 Decreased Sulphide Detoxification Capacity Is Correlated with An Impaired Butyrate Oxidation in Ulcerative Colitis (2009) (0)
Faecal bacterial molecular profiles of Crohn’s disease patients differ from their healthy relatives and matched healthy controls. (2007) (0)
W1089 Safety of Adalimumab in Global Clinical Trials of Patients with Crohn's Disease (2009) (0)
Adalimumab 160-/80-mg Induction Regimen is Associated With Better Outcomes Compared With the 80-/40-mg Regimen During Maintenance Therapy in Patients With Crohn's Disease (2011) (0)
Adalimumab Therapy maintains remission for up to 3 Years in patients with moderately to severely active Crohnʼs Disease: Results From an Open-Label Extension of CHARM: P-0121. (2009) (0)
The impact of infliximab therapy on intestinal mucosal expression of matrix metalloproteinase and ADAM genes in patients with inflammatory bowel disease. (2009) (0)
Diagnostic Accuracy of Methylene Blue Guided Chromoendoscopy in Patients with Suspicion of Dysplastic Barrett's Oesophagus (2008) (0)
Mo2049 Repeated Cycles of DSS Inducing a Chronically Relapsing Inflammation: A Novel Model to Study Fibrosis Using In Vivo MRI T2 Relaxometry (2012) (0)
T2 Relaxometry Distinguishes Acute Murine DSS Colitis From Chronic Relapsing Colitis. A Novel Tool to Assess Transmural Fibrotic Lesions (2011) (0)
Chapter five Regulatory macrophages induced by infliximab are involved in healing in vivo and in vitro (2011) (0)
anexperimental study indogs (1981) (0)
OP12 Multiple functional variants at the 3p21 locus contribute to ulcerative colitis: Results from a European consortium (2012) (0)
Volatile organic fermentation products in the mouth (1996) (0)
Tu1836 Identification of DSG3, MAGI1 and TFF1 As Functionally Important Genes in Inflammatory Bowel Disease Pathogenesis (2015) (0)
W1244 Molecular Reclassification of Crohn's Disease by Cluster Analysis of Genetic Variants (2010) (0)
Influence of dietary-protein supplements on formation of fecal volatile metabolites (1993) (0)
Mo1719 Strong Mucosal Upregulation of AIM2 and IFI16 Inflammasomes in Patients With Active Inflammatory Bowel Disease (2014) (0)
Authors' response (2010) (0)
Long term administration of lactulose can stimulate Bifidobacterium adolescentis in vivo and influence the colonic urea-nitrogen metabolism (2005) (0)
Authors' response (2011) (0)
Infectious enterocolitis: diagnostic aspects and relation to chronic idiopathic inflammatory bowel disease (1991) (0)
Expression of CD40 and CD40L in inflammatory bowel disease (1998) (0)
Towards trough level guided dose optimisation of adalimumab (2012) (0)
Differential effect of fecal water on butyrate oxidation in HT-29 cells and human colonic biopsies (2012) (0)
S1208 Altered Colonic Metabolite Fingerprint in Chronic Kidney Disease As Compared to Healthy State (2009) (0)
Hémostase endoscopique des ulcères hémorragiques : comparison of endoscopic polidocanol injection and YAG laser therapy for bleeding peptic ulcers. (1990) (0)
Influence of nicotine on the intestinal transit of a liquid meal (2000) (0)
Tauro-'/a, 1 2ac=dihydroxy-S~-cholanic acid as internal standard in the gas-liquid chromatographic analysis of bile acid methyl ester acetates (1983) (0)
Infliximab Improves Quality of Life in UC Regardless of Baseline Disease Activity: 1043 (2006) (0)
Crohn ' s colitis . Bile acid studies in patients with (2006) (0)
Tu1922 Genetic and Clinical Characterization of 41 Multiple-Affected IBD Families (2014) (0)
P005 Restoration of Foxp3 regulatory T cells in blood correlates with clinical response to anti-TNF therapy for IBD (2012) (0)
Pre-operative treatment with infliximab does not reduce the length of resected bowel in Crohn's disease (2003) (0)
TREATMENT OF INFLAMMATORY BOWEL DISEASES (IBD) WITH INFLIXIMAB (2004) (0)
Efficacy of Adalimumab for the Treatment of TNF-Antagonist-Naïve Patients with Crohnʼs Disease: Subanalysis of a Phase III Trial (2008) (0)
Long-Term Outcome after Discontinuation of Infliximab in Patients with Crohn’s Disease Achieving Clinical Remission (2013) (0)
Safety and tolerability of one hour infliximab infusions in patients with IBD: retrospective analysis of a large single center cohor (2010) (0)
Endoscopic lasertherapy (ELT) for palliation of colorectal carcinoma: Analysis of risk factors influencing outcome (1997) (0)
Dietary intervention with lactulose is linked to band-specific changes in community fingerprinting profiles of the human faecal microbiota (2007) (0)
Reply to both letters (1993) (0)
Monocytes/macrophages of the human ileum in Crohn's disease a disturbed recruitment ? (1989) (0)
Interstitial Yag laser hyperthermia is more suitable for intrahepatic tumor destruction than alcoholisation (1989) (0)
Case presentation: Postoperative prophylaxis (2000) (0)
Role of Concomitant Immunosuppression in the Efficacy and Safety of Ustekinumab: Post-Hoc Analyses of UNITI (2018) (0)
Inhibition of Th17 but not of Tregs affects extracellular matrix deposition in chronic DSS colitis (2013) (0)
Case presentation: Steroid refractory colitis (2000) (0)
13 - WELCOME: A randomized, double-blind, controlled trial comparing certolizumab pegol 400mg every 2 weeks with every 4 weeks for maintenance of response and remission in patients with moderate-to-severe Crohn's disease with secondary failure to infliximab (2009) (0)
Approach to Upper Gastrointestinal Bleeding - When to Treat? (1990) (0)
Card15/Nod2 mutations in ulcerative colitis (Uc) and Crohn's disease (Cd) patients belonging to mixed Ibd-families: A distinct entity? (2003) (0)
Treatment of bleeding gastrointestinal telangiectasias with estragen-progesterone (1989) (0)
Nicotine and gastroduodenal permeability (2000) (0)
trough serum levels Predicting the response to infliximab from (2010) (0)
Tc99m-HMPAO white blood cell scintigraphy is useful in the assessment of the extent and severity of an acute exacerbation of ulcerative colitis (1998) (0)
How to evaluate atypical perinuclear anti-neutrophil cytoplasmic antibodies (pANCA) in patients with ulcerative colitis (UC)? Results of an inter-observer and inter-assay study (2003) (0)
4-1BB (CD137) is expressed in Crohn's disease patients and enhances proliferation of lamina propria T cells (2002) (0)
Adalimumab Induced and Maintained Clinical Remission in Patients with Crohnʼs Disease Independent of Baseline CRP Concentration: Subanalysis of the CHARM Study (2006) (0)
Immunological effector cells associated with the destruction of the autonomic nervous system in Crohn's disease (1989) (0)
Blockade of CD40 signaling improves experimental colitis in scid mice (1999) (0)
Endoluminal Fundoplication (Esophyx®) in GERD Patients Refractory to PPI Therapy: Effect On Symptoms, PPI Use and Distensibility (2009) (0)
P052 Inhibition of Th17 cells but not of Tregs affects extracellular matrix protein deposition in chronic DSS colitis (2013) (0)
The impact of major depressive disorder on the short-term and long-term outcome of Crohn's disease treatment with infliximab: a prospective study (2005) (0)
Subject Index Vol. 30, Suppl. 1, 2012 (2012) (0)
Diagnosis and treatment with endoscopy (1994) (0)
Clinical Benefit of Adalimumab Dose Adjustment for Patients With Moderately to Severely Active Crohn’s Disease in EXTEND: 1610 (2014) (0)
Scurvy in Whipple's disease: a rare complication of a malabsorption syndrome (1994) (0)
papers and notes on I (1981) (0)
A80 ENDOSCOPIC HEALING WITH USTEKINUMAB IN CROHN’S DISEASE: THE UNITI ENDOSCOPY SUB-STUDY (2018) (0)
Gastric metaplasia in the distal duodenum - Crohn's disease rather than peptic ulcer disease (1995) (0)
Gene expression of antimicrobial peptides in colonic mucosa of patients with inflammatory bowel disease before and after first infliximab treatment. (2008) (0)
Measurement of oro cecal transit time of a solid meal by use of lactitol and lactulose cake (1988) (0)
Microscopic lesions of the duodenum in Crohn's disease (1993) (0)
Optimising anti-TNF treatment on the basis of trough levels and anti-drug antibodies (2012) (0)
Sa1811 Assessment of the Microbiota in Microdissected Tissues of Ulcerative Colitis Patients (2013) (0)
The genetic prediction of the clinical response to infliximab in Crohn's disease (CD): A role for polymorphisms in the TNFa and LTA genes? (2002) (0)
W1278 Treatment With Extracorporeal Photopheresis (Ecp) Allows Steroid Withdrawal or Reduction in Patients With Steroid-Dependent Crohn's Disease (Sd CD) (2010) (0)
Mo1794 Predominant Intestinal Microbiota Predicts Postoperative Crohn's Disease Recurrence Following Ileocaecal Resection With Ileocolonic Anastomosis (2015) (0)
Influence of gastric-emptying on orocecal and small-intestinal transit-time (1994) (0)
P030 Continuous Adalimumab Maintenance Therapy Yields Better Outcomes than Induction and Reinitiated Therapy for Moderate to Severe Crohn's Disease: Subanalysis of Charm (2008) (0)
Modulating expression of Foxp3 correlates with clinical response to Infliximab: new mechanism of action for anti-TNF therapy in inflammatory bowel disease (2009) (0)
Infliximab for ulcerative colitis - Reply (2006) (0)
P446 Characterization of ulcerative colitis patients in the Golimumab PURSUIT-Maintenance study: post-hoc analyses of patients who maintained and did not maintain clinical response through week 54. (2017) (0)
Meal-to-meal variability of gastric emptying of solids in man (1996) (0)
P504 Familial aggregation in the response to anti-TNF in inflammatory bowel disease patients (2013) (0)
W1107 Surgical Closure of Crohn's Rectovaginal Fistulas in the Era of Biological Therapies (2009) (0)
Gastric empyting of solids and non-ulcer dyspepsia (1995) (0)
Lower gastro-intestinal hemorrhage: diagnosis and treatment. (1986) (0)
Infliximab Therapy Reduces Hospitalizations in Ulcerative Colitis Patients: 847 (2005) (0)
T1054 Analysis of Genetic Variants in Non-TPMT Genes to Explain Bone Marrow Toxicity During Azathioprine Therapy in Inflammatory Bowel Disease (2008) (0)
Blockade of CD28/CTLA-4-B7 costimulatory pathway in colitic SCID mice (2000) (0)
Operating Properties of Different Patient Reported Outcome Endpoints Combined With Endoscopic Evaluation: Data From EXTEND: 2259 (2015) (0)
W1238 Investigation of Crohn's Disease Associated Loci in Ulcerative Colitis Points Towards Common Susceptibility Genes in the TH17 Pathway and Innate Inmunity (2010) (0)
TECK and MADCAM-1 mucosal expression in active IBD : the effect of infliximab therapy (2009) (0)
Recto-vaginal fistulas in Crohn's patients can be successfully managed by aggressive systemic treatment and advancement flaps (1998) (0)
DOP031 A multicenter study to evaluate magnetic resonance enterography (MRE) for selection of Crohn's disease patients for inclusion into a therapeutic clinical trial (2014) (0)
DOP059 Reduction of fecal calprotectin levels and relationship to clinical parameters in the phase 2 study of laquinimod for the treatment of active moderate to severe Crohn's disease (2014) (0)
Interleukin-15 induces T cell activation in inflammatory bowel disease (1999) (0)
Seroreactivity to Elongation Factor EF-TS and to TrpR Binding Protein From Klebsiella Pneumoniae in Crohn's Disease and Ulcerative Colitis Patients (2011) (0)
Interassay and Interobserver Variability in the Detec- Tion of Anti-neutrophil Cytoplasmic Antibodies in Pa- Tients With (0)
associated diseases. Also, for patients with CD, treating physicians might need to consider "TNF implications" of all a patient's medicines. (2001) (0)
Influence of human intestinal fluid on the efficacy of P-gp related efflux carriers (2000) (0)
The prevalence of pancreatic autoantibodies (PAB) in an Belgian IBD population (2001) (0)
[Zieve's sydnrome]. (1976) (0)
Dose-dependent effect of cisapride on orocecal transit studied by the lactose-(13C)-ureide breath test (1998) (0)
Recurrence of Crohn's disease after ileocolonic resection : endoscopic assessment (1994) (0)
7 LONG-TERM EFFICACY OF INFLIXIMAB AND COLECTOMY-FREE SURVIVAL IN OUTPATIENTS WITH REFRACTORY ULCERATIVE COLITIS (2008) (0)
Efficacy of anti-TNF in comparison with metronidazole in the indomethacin-induced small bowel inflammation model (1998) (0)
Inflammatory bowel diseases (2012) (0)
Impact of Ileocecal Resection in Crohn's Disease Patients on Fecal Microbiota (2017) (0)
Intestinal mucosal gene expression of endothelial cell adhesion molecules in patients with inflammatory bowel disease before and after first infliximab treatment. (2010) (0)
IL-12 modulates regulatory T cells in vitro and in a model of colitis (2003) (0)
Mo1737 The Effect of Infliximab Therapy on the Tryptophan Metabolism and Indoleamine 2,3-Dioxygenase Expression (IDO) in Patients With Inflammatory Bowel Disease (2014) (0)
Long-term oral glutamine supplements have no effect on small intestinal permeability in Crohn's disease (1997) (0)
OP038 Impact of ileocecal resection in Crohn's disease patients on mucosal microbiota. (2017) (0)
CD40 can be a stronger costimulatory signal than CD80 in upregulating TNF production in pathological ileal Crohn's disease (1999) (0)
Genetics of inflammatory bowel disease: Contribution of the X chromosome (1998) (0)
Genetic polymorphisms in primary sclerosing cholangitis: a candidate gene study (2005) (0)
Corrigendum to “Rectal non-Hodgkin's lymphoma in an infliximab treated patient with ulcerative colitis and primary sclerosing cholangitis” [J Crohn's and Colitis 4 (2010) 683–6. Epub 2010 Jul 14] (2011) (0)
Testing Intestinal Function Possibilities Offered by 13 co 2 Breath Tests and Stable Isotopes (2006) (0)
Intestinal mucosal gene expression of endothelial cell adhesion molecules in patients with inflammatory bowel disease and the impact of infliximab therapy. (2010) (0)
Mo1365 Familial Aggregation in the Response to Anti-TNF in Inflammatory Bowel Disease Patients (2013) (0)
W1305 Efficacy and Safety Profile of Certolizumab Pegol: Results From the Compas Programme in Belgium (2010) (0)
ENDOSCOPIC INJECTION THERAPY. AUTHOR'S REPLY (1993) (0)
Different NSAIDS have different direct effects on human intestinal epithelial cells (1992) (0)
Authors' response (2010) (0)
Presence of pANCA in Crohn's patients with ''UC-like'' clinical, phenotype is related to disease activity (1997) (0)
P017 Infliximab Reduces Colectomy in Patients with Moderate-to-Severe Ulcerative Colitis: Colectomy Analysis from ACT1 and ACT2 (2008) (0)
P-0019: Long-Term safety of Certolizumab Pegol in Crohn's Disease: Integrated safety findings on serious adverse events of special interest (2008) (0)
Combining serologic antibodies ASCA and anti-ompC increasses sensitivity for Crohn's disease (CD) (2001) (0)
Prevention of duodenal-ulcer recurrence by pirenzepine 50 mg bid (1985) (0)
Cluster analysis of genetic variants enables reclassification of Crohn’s disease at the molecular level (2009) (0)
Are lympho-epithelial lesions the diagnostic hallmark of gastric marginal zone cell lymphomas (1999) (0)
Adalimumab Downregulates Markers of Inflammation in Patients with Moderate to Severe Ileocolonic Crohnʼs Disease: The Histologic Substudy of EXTEND: 1169 (2009) (0)
Increased expression of high endothelial venule characteristics by epithelial cells in Crohn's disease (1991) (0)
Mo1744 Ulcerative Colitis Patients With Endoscopic Healing After Infliximab or Vedolizumab Therapy Have Persistent Dysregulation in Colonic Mucosal Gene Expression (2015) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Prof. P. Rutgeerts?

Prof. P. Rutgeerts is affiliated with the following schools:

KU Leuven

Prof. P. Rutgeerts's Academic­Influence.com Rankings

Why Is Prof. P. Rutgeerts Influential?

Prof. P. Rutgeerts's Published Works

Published Works

What Schools Are Affiliated With Prof. P. Rutgeerts?

Prof. P. Rutgeerts's AcademicInfluence.com Rankings